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The nephrotic syndrome (NS) is characterized by massive proteinuria, edema 
and hypertriglyceridemia. It can appear as a primary or a secondary disease, 
idiopathic or familial, monogenic or complex, responsive to medication or 
progressing inevitably towards end-stage renal disease. As the manifestations of 
the disease are varied so is the etiologies behind it and still much remains to be 
discovered. However, structural compromise can be observed in the glomeruli 
of the NS patients, especially in podocytes, specialized epithelial cells of the 
glomerular filtration barrier. When causative genetic variants are found they are 
predominantly in the genes coding proteins involved in the structure and 
function of the podocytes. To date, over thirty podocyte protein-coding genes 
have been implicated. 
 
In this study we looked into genetic and cellular mechanisms in the podocyte 
underlying different forms of NS: congenital nephrotic syndrome of the Finnish 
type (CNF), steroid sensitive nephrotic syndrome (SSNS) and steroid resistant 
nephrotic syndrome (SRNS). Specifically, we used CNF kidney samples to study 
how the different compartments of the podocyte are affected by the lack of 
nephrin, characteristic structural component of the unique cellular junction of 
the podocytes (slit diaphragm (SDs)). We also looked into genetic variation in 
the podocyte protein coding genes in the Finnish SRNS patients to map out the 
variant spectrum and to see if this population shows difference to other 
populations. In addition, we aimed to find genetic and clinical markers 
predicting the course and severity of SSNS, which would have significant clinical 
value. 
 
The analyses were carried out using an array of molecular biological methods. 
Protein expression was studied using immunohistochemistry and light 
microscopy, genetic variants with PCR and sequence analysis. In addition, 
immunoprecipitation and western blot analyses were carried out to study the 
functionality of a particular variant. Genome wide sequencing analysis was 
carried out to gain wider perspective on the variant spectrum in NS patients. 
 
Our results showed that the lack of nephrin leads to widespread effects in the 
podocyte on protein level, especially on the expression of other proteins of the 
SD. In other compartments of the cell (basal membrane, actin cytoskeleton, 
apical membrane) the effect was clear but considering the profound structural 
damage seen in CNF the orders of magnitude of the observed changes were 
modest. 
 
We also showed that the analyzed clinical features or variants in these key genes 
coding podocyte proteins cannot reliably predict severity of SSNS. Children with 
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difficult disease (multiple relapses, dependence on steroids) are more likely to 
suffer from NS in adulthood but other correlations between early patient 
features and prognosis could not be made. Single nucleotide polymorphisms 
(SNP) analysis of children with idiopathic NS revealed that variants in some 
genes (e.g. MDR1) may be useful in predicting responsiveness to steroids but 
the correlation is not sufficiently strong to warrant routine clinical testing. We 
found few causative variants in patients with idiopathic SRNS but did uncover a 
de novo NPHS2 variant co-segregating with familial dominant SRNS and 
unusual course of the disease. 
 
Healthy function of the podocyte relies on interaction and communication 
between multitudes of protein components in the different compartments of the 
cell. If any of these components are faulty it may cascade into widespread 
podocyte damage and proteinuria. The precise nature of the defect may play a 
significant role in the disease phenotype and not only the function of the 
damaged gene but also the nature of the variant ought to be considered when 
carrying out genetic analysis.  
 
Not in all cases causative variants or precise faulty structures can be identified. 
The genetic factors behind complex traits remain elusive, and even though some 






1. Review of Literature 
 
1.1 Structure and function of the Nephron 
 
1.1.1 An Overview 
 
Kidneys are two bean-shaped organs of the vertebrates, located at the rear of the 
abdominal cavity each side of the spine. Their key role is to produce urine, 
which serves several regulatory and homeostatic functions. These include the 
removal of excess water, organic molecules, and other waste products of 
metabolism as well as regulation of electrolytes, maintenance of acid-base 
balance and regulation of blood pressure via maintaining the salt and water 
balance.  
 
The functional unit of the kidney is nephron and there are approximately one 
million nephrons in each human kidney (1). In nephron, under pressure, blood 
is filtered first into primary urine and then further refined into actual urine that 









The nephron is composed of two compartments: the glomerulus and the tubule 
(Figure 1). The function of the glomerulus is to conduct the primary urine 
filtration, to ensure dependable passing of small solutes while retaining blood 
cells and proteins the size of albumin and larger in the circulation. The tubule 
reabsorbs water and small molecules such as electrolytes, peptides and organic 
molecules from the primary urine based on the needs of the body and thus 
defines the final concentration and volume of urine, which in healthy adults 
totals to approximately 1-1,5 liters per day.  
 
In the glomerulus the afferent arteriole branches into a tuft of small capillaries 
through the walls of which the plasma is filtered (Figure 2). Surrounding the 
tuft is the expanded end of the proximal tubule, Bowman’s capsule. Inside of the 
capsule is the urinary space, Bowman’s space, which gives into the proximal 





Figure 2  The glomerulus. Adapted from the image of Somlo and Mundel (3) 
 
 
The tubule is divided into segments that differ structurally and functionally: the 
walls of different segments have different cell types to accommodate the 
reabsorption of different substances. Proximal tubule is responsible for the most 
reabsorption of water as well as the reabsorption of small proteins, amino acids, 
glucose, and electrolytes. The loop of Henle establishes and maintains osmotic 
gradient in the renal medulla: its thin descending limb is freely permeable to 
water and ions while thin ascending limb is much less permeable to water but 
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very permeable to salts and thick ascending limb is completely impermeable to 
water and actively transports salts from the filtrate. The distal tubule has two 
portions: the straight portion also plays a role in establishing osmotic gradient 
by being impermeable to water while removing salt, and the convoluted portion 
is responsible for the removal of calcium from the lumen as well as the 
remaining sodium and chloride and it also actively secretes hydrogen and 
potassium ions into the lumen. The distal convoluted tubule gives into the 
collecting duct where more water is reabsorbed and the final volume of urine 
defined. 
 
The collecting duct leads into the renal calyces from where the urine is moved to 
the ureter that carries it further to the bladder. 
 
1.1.2 Glomerular filtration barrier 
 
The plasma is filtered through the glomerular capillary wall. The barrier 
between circulation and urinary space has three layers: 1) the fenestrated 
endothelium, 2) glomerular basement membrane (GBM) and 3) the foot 
processes of glomerular visceral epithelial cells, podocytes (Figure 3). The 
salient function of the glomerular filtration barrier is to prevent the loss of blood 
cells and proteins into the urine, while efficiently and dependably allowing the 
passage of solutes to be disposed. The glomerular filtration barrier (GFB) 
functions under tremendous workload as approximately 180 l of primary urine 
is formed each day. The filtration of molecules is thought to be shape, size and 
charge selective (4), although the last is still debated (5). Each layer of the 
barrier has an essential role in the filtration process and their functions are 
interwoven as they cross talk and act as a whole. Faults in any of the three layers 





Figure 3 The glomerular filtration barrier. Adapted from the images of Haraldson et al. 
(6), Hallmann et al. (7), Machuga et al. (8) and Miner (9). 
 
 
1.1.3 Fenestrated endothelium 
 
The defining feature of the endothelial cells lining the luminal side of the 
glomerular capillaries is the transcellular fenestration. The fenestrae are 60-80 
nm in diameter and occupy 30-40% of the cell surface (10) and do not possess 
diaphragms (11). They play a salient role in accommodating the high water 
permeability of the endothelial cells, which is essential for the filtration function 




 Molecules anchored to the endothelial cell luminal surface form polyanionic 
hydrated mesh called glycocalyx that covers both the fenestral and 
interfenestral domains. Glycocalyx is a complex structure composed of 
proteoglycans, glycoproteins and sialic acids (12). It adsorbs plasma molecules 
including albumin and orosomucoid and secreted proteins such as hyaluronan. 
Together the glycocalyx and the adsorbed components are known as endothelial 
surface layer (ESL) (13). 
 
The role of glomerular endothelial cells and ESL in plasma protein retention has 
been debated. For a long time it was thought to be negligible, mainly due to 
fenestration pore size being too large to prevent the protein from passing 
through, but in recent years this attitude has started to change (14, 15). While 
the diameter of the fenestrae is much larger than that of albumin (60-80 nm vs. 
8 µm), biophysical studies show that water and small solutes do not permeate 
through them as efficiently as expected and the macromolecule permeability of 
fenestrated capillaries is not higher than that of un-fenestrated capillaries. The 
glycocalyx is thought to create this resistance to permeation by “plugging” the 
fenestrae (14, 16, 17). 
 
All layers of GFB are interconnected and function as a whole. Glomerular 
endothelium and the formation of ESL are regulated by podocyte-secreted 
proteins including vascular endothelial growth factors and angiopoietin-1 (18-
22). Reciprocally, as glycocalyx reacts to shear stress caused by the plasma flow, 
the behavior of the endothelial cells is modulated to secrete mediators such as 
nitric oxide that may affect podocyte function (23, 24). 
 
1.1.4 Glomerular basement membrane 
 
The glomerular basement membrane (GBM) is a specialized, sheet-like 
extracellular matrix located between fenestrated endothelium and podocytes. 
All basement membranes have the same main components: laminin, type IV 
collagen, nidogen and heparan sulfate proteoglycan (25). The GBM is unusually 
thick for a basement membrane and contains particular members of these 
general protein families (26). 
 
Laminin is a heterotrimeric protein, ubiquitous in basement membranes. It 
contains three chains (α, β, γ), and all of them have several isoforms that form 
nonrandom combinations. At least 15 different heterotrimers are known (27). In 
mature GBM the predominant isoform is laminin-521 (composed of α5, β2 and 
γ1 chains). Laminin has domains that contain binding sites for cell surface 





Type IV collagen is also a trimeric extracellular matrix protein. It is formed of 
three α-chains. There are six genetically different α-chains that trimerize in 
specific stoichiometries to form different types of network-forming building 
blocks. After being secreted into the extracellular matrix, they polymerize and 
become crosslinked to form a network within the GBM (9). Basement 
membranes can form without type IV collagen but it is essential for the long-
term stability of the structure (29). In mature GBM the major type IV collagen 
isoform is α3α4α5, although (α1)2α2 exists as a minority (30). 
 
There are two nidogen proteins, nidogen-1 and nidogen-2, both common 
basement membrane proteins. They are at least partially redundant, and 
knockout mice missing either of two are viable and fertile (31, 32). Nidogen-1 
binds both laminin and collagen type IV, and it has been speculated that its role 
is to connect these two separate networks (33). However, while deletion of both 
nidogen proteins simultaneously results in perinatal lethality, the basement 
membranes seem to be able to form in their absence (34). Thus, it is unclear 
how essential nidogen actually is to GBM. 
 
The major heparan sulfate proteoglycan in GBM is agrin, although it also 
includes perlecan (35). Agrin has a high negative charge that is thought to 
majorly contribute to the negative charge of GBM (36). Classically it has been 
thought that the negative charge of the GBM repels the negative albumin and 
thus contributes to its retention. However, this view has been challenged, as it 
has been shown that removal of agrin and perlecan doesn’t affect filtration (37, 
38). Other study suggested that GBM negativity has more significant role in 
retention of small, 20-35Å proteins but not in retention of the larger ones (39). 
 
GBM is structured in three layers: between lamina rara interna (close to the 
endothelial cells) and lamina rara externa (close to the podocytes) lays lamina 
densa. The laminas rara are rich in heparan sulfate proteoglycans while lamina 




The visceral epithelial cells, podocytes, lay on the urinary space side of the 
glomerular capillaries. Podocytes are terminally differentiated, unique cells of 
particular shape: from the cell body extends primary processes which then 
divide further into secondary processes and finally into narrow foot processes 
(Figure 4). The foot processes of adjacent cells are interdigitated and the narrow 
slit between them is bridged by a specialized sheet-like structure, slit diaphragm 
(SD). The basal membrane of the foot processes is the only part of the podocyte 
attached to the GBM, and thus the foot processes along with the SD form the 
last layers of glomerular filtration barrier. The architecture of the foot processes 
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is specific and dynamic and maintained by actin cytoskeleton. Each domain of 




Figure 4 The podocyte on the surface of a glomerular capillary. Adapted from the image 
of Nilius et al. (40). 
 
 
While the fenestrated endothelium and GBM may block large portion of 
proteins from passing through GFB, the essential role of podocytes and SD is 
highlighted by the fact that numerous mutations in genes coding for foot 
process- and SD-specific proteins lead to massive proteinuria. This speaks for 
the importance of podocyte signaling properties and communication between 
the three layers of GFB. 
 
1.1.5.1 Basal and apical membrane domains 
 
Essential driving force in the renal filtration is the hydrostatic and oncotic 
pressure in the glomerular capillaries. To cope with the pressure the podocyte 
foot processes must adhere tightly to the GBM. Several basal membrane 
receptors find their ligands among the components of the GBM and they form 
the binds that keep the podocytes in their place. The primary adhesion receptors 
in this task are the integrins, which bind laminin-521 of the GBM. In the cytosol 
of the foot processes, integrins bind a variety of proteins including signaling and 
force-transducing molecules that associate with the components of the 
cytoskeleton (41). As the cytoskeleton is the main stress-baring component of 
the cell, this tight connection between extracellular matrix and cytoskeleton 
provides physical reinforcement, which enables the cell to withstand 




The adhesion of podocyte to GBM is regulated by altering integrin activation, 
clustering and expression in the basal membrane as well as affecting its lateral 
association with other membrane proteins (42-44). The most abundant integrin 
in the basal membrane of the podocyte is integrin α3β1. It is thought to play a 
role in podocyte development as mice lacking the α3 or β1 subunit die soon after 
birth or already in utero, although the damage is not limited to the kidney. 
Podocyte-specific deletions of the genes coding for these proteins lead to GBM 
abnormalities and foot process effacement (45-48). In addition to integrin α3β1, 
α2β1 and αvβ3 are expressed in the podocyte basal membrane. α2β1 binds 
collagen IV of the GBM and its deficiency is associated with abnormal GBM-
podocyte phenotype in mice (49). The significance of α2β1 is not fully 
understood but it seems to be minor compared to α3β1. Integrin αvβ3 binds 
vitronectin and collagen but mice lacking it do not develop overt primary kidney 
abnormalities so its role in podocyte adhesion to GBM is probably not major 
(50-52). Curiously, enhanced activation of integrin αvβ3 by soluble urokinase 
receptor causes foot process effacement and proteinuria in mice and humans 
(53, 54). Loss of β1-subunit also leads to an increase in αvβ3 activity that may 
add to pathogenicity of β1 mutations (55). 
 
Another connection between the GBM and the actin cytoskeleton occurs 
through dystroglycan, a membrane protein that is composed of heterodimeric 
complex of extracellular α- and transmembrane β-subunits. In GBM, 
dystroglycan binds proteins such as laminin and agrin, and in cytoplasm, it is 
interacting with utropin that connects to the actin cytoskeleton (56-58). The 
relevance of dystroglycan and its function in the podocyte is not yet clear. Its 
expression is diminished in some forms of experimental and human nephrotic 
diseases, and it has been suggested to play a role in positioning and organizing 
the proteins of basal membrane (59). Dystroglycan knockouts die early in 
embryonic development due to fragility of basement membranes (60), while 
defective glycosylation of α-subunit is reported to inhibit the binding of laminin 
and agrin resulting in the flattening of the foot processes (61). However, another 
study found that podocyte-specific dystroglycan deletion did not result in 




The shape and architecture of podocyte foot processes is essential for their 
integrity and function as a structural component of the filtration. An additional 
challenge to the podocyte structure is brought by its dynamic nature: podocytes 
have stress-activated receptors and in vitro stretch initiates structural changes 
(63, 64). Podocyte may also have a contractile role in controlling blood flow, as 
the foot processes encircle the capillaries (65, 66). All this demands a highly 




The podocyte cytoskeleton has different composition and function in different 
parts of the cell. The cell body and major and secondary processes contain 
vimentin-rich intermediate filaments, while the larger microtubules form 
organized structures along the major and secondary processes. Intermediate 
filaments are tension-bearing elements that help to maintain cell shape and 
rigidity (67). The microtubles are polymers of α and β tubulin that grow and 
shrink in a highly regulated fashion in response to intra- and extracellular 
signals. They play an essential role in foot process formation (68, 69) and carry 
out multiple functions including regulation of cell motility, vesicular transport, 
the maintenance of cell shape and polarity as well as organization and 
positioning of membrane organelles (67).  
 
The podocyte foot processes contain long actin fiber bundles that run cortically 
and continuously from one foot process to the next (70). Adaptor proteins 
connect the actin cytoskeleton to the intercellular space and the SD as well as to 
the basal membrane and the GBM (71). 
 
Actin organization and dynamic reorganization is an integral tool in regulating 
the shape and movement of podocytes, as actin filaments bring them internal 
mechanical support, tracks for movements of materials, and force to drive cell 
motility. Monomeric, globular actin is soluble but as it polymerizes it forms 
insoluble filaments that have considerable mechanical strength (67, 72). Actin 
can exist as bundles or as networks, and over hundred different proteins tightly 
regulate all its processes including initiation of new filaments from monomers 
and adding branch to existing filaments. Many of these proteins are slit 
diaphragm related, including nephrin, CD2-associated protein (CD2AP) and 
calcium transporter transient receptor cation channel, subfamily C, member 6 
(TRPC6). 
 
α-actinin-4 (ACTN4) is an actin-binding protein with strong expression in 
podocytes that cross-links actin filaments into contractile bundles (73). Through 
adaptor proteins such as densin and integrin-linked kinase (ILK), it is also a 
part of the interaction chains connecting the actin cytoskeleton to the SD and 
basal membrane. It even interacts directly with integrin α3β1 (70). α-actinin-4 is 
regulated by extracellular signals that lead to its phosphorylation and decrease 
its affinity to actin. Mutations in α-actinin-4 cause nephrotic syndrome and are 
centered on the actin-binding domain. These mutations cause an increase in the 
α-actinin-4 binding-affinity to actin and change mechanical properties of the 
cytoskeleton (74). 
 
Inverted formin 2 (INF2) has the ability to both polymerize and depolymerize 
actin and this function gives it an important role in the regulation of cytoskeletal 
remodeling (75). Mutations in INF2 cause nephrotic syndrome and the majority 
of known mutations are located within the diaphanous inhibitory domain that 
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mediates the INF2 autoinhibition through interaction with the C-terminal 
diaphanous autoregulatory domain (76, 77).  
 
Proline-rich, actin-associated protein, synaptopodin, has an essential part in 
regulating foot process shape and motility. Synpatopodin binds ACTN4 and 
regulates its actin-bundling activity, and adaptor protein CD2AP that binds 





1.1.5.3 Slit Diaphragm 
 
Slit diaphragm is a complex, sheet-like structure composed of numerous 
proteins. It bridges the gap between adjacent foot processes and is the last 
component of the filtration barrier. Besides an essential structural component 
of the GFB, the SD is a platform for signal transduction from the extracellular 
space into the intracellular, and to the actin cytoskeleton and thus plays a 
pivotal role in dynamic actin remodeling and in altering the foot process 
architecture, as well as in several other cellular functions (80). Conditions that 
lead to the breakdown of the SD result in heavy proteinuria. 
 
SD is localized to the lateral membrane of the foot processes, in the lipid rafts, 
particular microdomains of cell membrane rich in cholesterol, 
glycosphingolipids and glycosylphosphatidylinositol -anchored proteins (81, 
82). The lipid rafts recruit and cluster membrane proteins in dynamic and 
selective manner and thus provide molecular frameworks for numerous 
biological processes including endocytosis, exocytosis, cell adhesion, and signal 
transduction (82). However, the role of lipid rafts in these processes is not to be 
just a platform for molecules: often the function of the proteins depends on 
their association with lipid rafts (83). 
 
A characteristic component of the SD is nephrin. It is a 185 kDa-transmembrane 
protein with eight extracellular immunoglobulin domains, one fibronectin motif 
and a short cytoplasmic tail (Figure 5). It forms a homodimer with a nephrin 
molecule from a foot process on the other side of the gap (84). This nephrin 
bridge is thought to be the backbone of the SD; missing or displaced nephrin 
leads to dissolved SD (85). In addition to being an important structural 
component of the SD, nephrin also has a function in signal transduction. In its 
cytosolic part nephrin has six conserved tyrosine residues that are 
phosphorylated by Src family kinase Fyn (86). Through adaptor proteins 
phosphorylated nephrin interacts with actin cytoskeleton and affects several 
cellular processes including cytoskeletal reorganization, cell growth and 







Figure 5 The structure of NPHS1 gene and nephrin protein 
 
Neph1 is a founding member of family of proteins homologous to nephrin. Their 
precise function is not yet fully understood but along with Neph1, Neph2 and 3 
are expressed in podocyte. With five Ig-domains and no fibronectin motif the 
Neph proteins are significantly smaller than nephrin, too small probably to 
reach over the slit gap to form homophilic interaction in trans configuration 
(88). However, homophilic interaction in cis conformation is suggested, as is 
heterophilic interaction with nephrin in both cis and trans configurations (89, 
90). Nephrin/Neph1 interaction is an important determinant for glomerular 
permeability (91), and it is also involved in the signal transduction to induce 
actin polymerization (92). Based on experiments in Drosophila melanogaster, it 
is speculated that Neph1 is involved in patterning of the SD and in signaling. 
Neph1 knockout mice die perinatally (93). However, unlike nephrin, expression 
of which is limited to kidney, Neph1 is expressed in multiple organs, including 
kidney, brain, placenta, gut, heart and lung (94). So far podocyte-specific Neph1 
knockout studies have not been published. 
 
Protocadherin Fat1 is also located in the SD. In vitro studies indicate that 
mammalian Fat1 is involved in planar cell polarity and directed actin-dependent 
cell motility (95). Although its precise function in the SD is not yet fully 
understood, these functions could make it salient regulator of foot process 
structure and dynamics. Loss of Fat1 leads to massive proteinuria and early 
perinatal lethality in mice (96) 
 
Another SD-located protein P-cadherin is a member of cadherin superfamily 
that is known for mediating homophilic cell-cell interactions. This could be its 
role in SD as well. However, little evidence exists on P-cadherin's function in the 
SD. P-cadherin deficient mice do not seem to have an aberrant renal phenotype 
(97) and a study was unable to show in vivo or in vitro association of P-cadherin 
to either nephrin or Neph1 (98). More is known of P-cadherin’s interaction with 
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adaptor protein β-catenin that stabilizes the SD and maintains its integrity (99, 
100). 
 
In addition to the proteins with extracellular domains that physically form the 
protein bridge, essential for the integrity and function of the SD are the adaptor 
proteins that connect the structure to the intracellular domains of the foot 
process. Podocin is located in the cell membrane at the insertion site of the SD. 
It has one transmembrane region and two cytosolic ends, which leads to a 
hairpin like structure (101) (Figure 6). The cytosolic ends bind proteins, 
including nephrin and Neph1, and it is presumed that the key function of 
podocin is to anchor nephrin to correct location in the lipid rafts (102). In 
addition to SD proteins podocin binds and regulates cation channel TRPC6, 
which is involved in the mediation of pressure sensation in the podocytes (103). 





Figure 6 The structure of NPHS2 gene and podocin protein 
 
 
CD2AP is expressed primarily in the cytosolic side of SD. It binds both nephrin 
and podocin and also the actin cytoskeleton forming a direct connection 
between the SD and the cytoskeleton. It is also involved in the SD signal 
transduction function. CD2AP and nephrin interact with a subunit of 
phosphoinositide 3-kinase (PI3K), which in turn activates intracellular Akt 
kinase pathway. This is needed in regulation of actin dynamics and cell survival 
(104). In animal models as well as in few human patients mutations in CD2AP 
gene have been associated with proteinuria. 
 
During development, the junction between podocyte foot processes evolves 
from a tight junction to a modified adherens junction (SD) and contains protein 
components from both types (98, 105, 106). Zona occludens -1 (ZO-1) is a 
membrane protein that is characteristic for cytoplasmic surface of tight 
junctions in epithelial and endothelial cells. In podocytes, it is found in the in 
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insertion of the SD and is linked to the actin cytoskeleton forming another 
connection between the two domains. In an animal model, redistribution of ZO-
1 was associated with ultrastructural changes in the foot processes and apical 
displacement of SD (107). 
 
There are two Nck proteins in the podocyte, Nck1 and Nck2, with highly 
redundant functions. Mouse studies show that Nck proteins are required for 
normal filtration barrier development as well as for its maintenance in mature 
state (108, 109). The Nck proteins have a SH2 domain, that is capable of 
interacting with phosphorylated tyrosine residues, and SH3 domains, which can 
recruit other proteins. In SD, the SH2 domain of Nck interacts with the several 
Src-family kinase Fyn-phosphorylated tyrosine residues in the cytosolic end of 
nephrin. The SH3 domains of Nck bind neuronal Wiskott-Aldrich syndrome 
protein (N-WASp) and N-WASp, in its turn, activates Arp2/3 complex and 
cortactin, thus connecting nephrin-Nck complex to the actin cytoskeleton (108). 
Nck and its actin-regulating associates are recruited to phosphorylated nephrin 
when rapid actin polymerization and cytoskeletal reorganization is required 
during development and injury repair (110). In a steady state, nephrin-Nck 
interaction may be rarer compared to predominant nephrin-CD2AP interaction 
(111, 112).  
 
β-catenin is adaptor protein that forms a complex with P-cadherin to stabilize 
the adherens junction and maintain its integrity as well as link it to the 
cytoskeleton (99, 100). In association with Wnt β-catenin is also a key regulator 
of gene expression via binding to transcription factors. Binding Wnt ligand 
leads to dephosphorylation and stabilization of β-catenin, which allows it to 
translocate into the nuclei and stimulate the transcription of Wnt-targeted 
genes (113). In podocytes, Wnt/β-catenin signaling pathway plays a salient role 




Leakage of protein to urine is often the first sign of many renal conditions, and 
functions as an independent risk factor for development of end stage renal 
disease. It is also associated with non-renal conditions, such as cardiovascular 
disease, and is a predictor of all-cause mortality rates. While some reports have 
looked into the role of the proximal tubule and its protein uptake in the 
development of proteinuria, the vast majority of studies have placed the blame 
on the GFB. Indeed, the genetic injuries underlying many proteinuric kidney 
diseases are found in proteins involved in the GFB function, especially in those 




1.2.1 Endothelium and proteinuria 
 
While several inherited kidney diseases have found their genetic cause in the 
components of GBM, podocyte SD and actin cytoskeleton, damage to 
endothelial cells may play a role in acquired kidney disease.  
 
Mechanisms that lead to loss of function in glomerular endothelium include 
reduction of density of fenestrae and alteration in their size, swelling of the 
endothelial cell and encroachment of the capillary lumen and thus increase in 
the shear forces (112). However, the key mechanism to induce proteinuria seems 
to be alterations in the glycocalyx of the endothelial cells. One study showed 
that an injection of lipopolysaccharide (LPS) (used as a model for sepsis) caused 
injury to endothelium resulting in acute kidney failure in mice. Even though the 
LPS-induced damage included albuminuria, no alteration in podocytes 
(including morphology, SDs, number, size etc.) was seen in electron microscopy 
(116). LPS injection resulted in an increase in heparanase that degrades heparan 
sulphate glycoproteins of the glycocalyx and in a reduction of sialic acid 
containing proteoglycans in the ESL (116). Other studies found that reduction of 
ESL hyaluronan by hyaluronidase and inhibition heparan sulphate 
glycosaminoglycan synthesis by high glucose lead to increased albumin 
permeability (117, 118). 
 
Other conditions that damage glomerular endothelium and lead to proteinuria 
include thrombotic thrombocytopenic purpura, diarrhea-associated hemolytic 
uremic syndrome, atypical HUS and preeclampsia (115, 119-122). 
 
1.2.2 GBM and proteinuria 
 
What and how large a role GBM plays in protein retention in healthy kidney is 
still unclear but genetic defects in its key components are known to result in 
proteinuric conditions. Mutations in LAMB2, gene coding for laminin β2 chain, 
leads to Pierson syndrome, a congenital nephrotic syndrome (CNS) associated 
with variable ocular and neurological manifestations (123). Pierson Syndrome 
follows autosomal recessive (AR) inheritance pattern and a majority of the 
causative mutations are truncating ones that are distributed equally to all exons 
(124). The truncating mutations lead to the reduction of β2 chain and thus to 
reduction of laminin-521 trimer, faulty GBM and proteinuria (125). Missense 
mutations and small inframe deletions in LAMB2 are reported in patients with 
milder disease phenotype (126, 127). The missense mutations are clustered in 
N-terminal globular laminin domain, important in intermolecular interactions 
(124). 
 
Mutations in the genes coding for any of the collagen IV α3, α4 or α5 chains can 
result in damaged GBM. Depending on the type of mutation, the damage can 
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vary from mild thin membrane disease to severe Alport syndrome. The thin 
membrane disease follows autosomal dominant (AD) inheritance pattern and is 
caused in 40-50% of patients by heterozygous null mutations in COL4A2 or 
COL4A4 (coding for α3 and α4 chains of type IV collagen, respectively) (9). 
Patients express hematuria, but the disorder does not usually progress or need 
treatment, although elevated risk of proteinuria and hypertension exists (128). 
In a homozygous state, the same mutations cause AR Alport syndrome 
characterized by hematuria, eventual renal failure and lamellated GBM as well 
as hearing loss and ocular abnormalities (128) Majority of patients also suffer 
from proteinuria. AR mutations of COL4A3 and COL4A4 are found in 15% of 
Alport syndrome patients, 85% have mutations in X-chromosomal COL4A5 
(128). 
 
It has been thought that the contribution of GBM to GFB is charge selectivity 
based on the negative charge of both GBM and albumin. However, in recent 
years this view has been questioned. For instance, one study showed that the 
deletion of negatively charged heparan sulphate proteoglycan agrin dramatically 
reduced the anionic charge of GBM but did not affect albumin filtration (129). 
Another study suggested that charge plays a minor role and affects mainly small 
pores and thus small proteins of 20-35Å (39). 
 
1.2.3 Podocytes and proteinuria 
 
Podocytes are essential for the filtration barrier integrity and their injury 
typically results in proteinuria. Mutations in many podocyte proteins, especially 
in those involved with the SD and actin cytoskeleton regulation are mutated in 
different forms of nephrotic syndrome (NS). 
 
In response to injury it is characteristic for podocytes to undergo vast changes 
in appearance. The most general type of change is called foot process 
effacement (FPE), which is seen in most cases of proteinuric kidney diseases 
from mild steroid sensitive nephrotic syndrome (SSNS) to severe CNS and 
experimental animal models. In its early stage it is characterized by loss of the 
interdigitated structure of the foot processes that retract into short cell 
projections with undefined shape (130). The number and width of the slit pores 
appears to be decreased and SDs are disrupted: lost or displaced from their 
usual position or replaced with other type of junction, typically occludens-type 
junction (131-133). Although the changes in the podocyte structure in FPE are 
drastic it is notable that the state is reversible. In experimental models FPE and 
its reversal have been seen in mere minutes after induction (134). 
 
As the FPE progresses, the foot processes merge first with the primary processes 
resulting in flattened, disc-like appearance of the projections covering the GBM, 
and then with the cell bodies. At this stage the cell bodies no longer float in the 
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filtrate of the Bowman’s space but are broadly attached directly to the GBM and 
in many places the subpodocyte space is mostly disappeared (135). In the final 
stage of FPE development, the cytoskeleton is rearranged into a basal 
cytoskeletal “mat” in close proximity to the GBM. It is composed of highly 
organized densely interwoven microfilaments crosslinked by α-actinin positive 
densities (135, 136). α-actinin appears to play an integral role in this cytoskeletal 
rearrangement, as in rats with puromysine aminonuclease nephrosis its 
expression is reported to be induced before FPE and proteinuria (137). The 
intact podocyte foot processes are anchored to the GBM by integrins and 
especially α3β1-integrin. In a FPE model in cultured podocytes, α3β1-integrin is 
downregulated while αvβ3-integrin is upregulated. It appears that αvβ3-integrin 
increases the cultured podocytes ability to withstand mechanical stress (138). 
 
One suggestion is that instead of a primary injury FPE is actually protective 
response to injury, an attempt to prevent podocyte detachment (133). There are 
about 800 podocytes per glomerulus and even healthy glomeruli lose podocytes 
during a lifetime. In normal circumstances the rate of excretion is low enough 
that a person is sufficiently sustained until advanced age. Several studies 
suggest that in NS as well as in animal models the rate of depletion increases 
dramatically and is preceded by FPE. Podocytes are terminally differentiated 
postmitotic cells that cannot proliferate or be generated from other glomerular 
cells (133, 139). As podocytes are essential for kidney function it is possible that 
mechanisms including FPE have developed to prevent their loss.  
 
Traditionally, the major mechanism for podocyte loss in progressive glomerular 
disease is thought to be apoptosis (140-142). This view has been challenged and 
it is suggested that podocytes in situ detach as viable cells that are lost due to 
podocytes inability to stay attached to GBM (133, 143). However, while many do 
think podocytopenia is an important determinant of a late stage glomerular 
injury, other studies have found no evidence of the phenomenon (144, 145).  
 
1.3 Proteinuric kidney diseases in children 
 
Nephrotic syndrome (NS) is characterized by massive proteinuria 
(>40mg/h/m2), hypoalbuminemia (<25g/l), hyperlipidemia and edema (146). 
While NS often occurs as a secondary feature to systemic a condition to 
glomerulonephritis or vasculitis, here we concentrate on primary childhood-
onset NS diseases. Primary NS can occur as an inherited, familial condition or 
as an idiopathic disease. Different NS entities are typically categorized based on 
responsiveness to steroid medication and histology. Typically, sensitivity to 
steroids is associated with minimal histological changes and thus it is often 
synonymously called minimal change nephrotic syndrome (MCNS). However, 
in some cases SSNS is associated with more severe histology, such as focal and 
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segmental glomerulosclerosis (FSGS) or diffuse mesangial sclerosis (DMS) that 
are usually associated with steroid-resistance. Likewise, sometimes steroid-
resistant NS (SRNS) has minimal histological changes. It is possible that in 
some cases the severity of the histology depicts more the stage of development 
of a disease than separate disease entities. However, it is reported that only 1-
3% of patients who initially respond to corticosteroid treatment develop steroid 
resistance later (147).  
 
As the clinical manifestations of different forms of NS are varied so are the 
genetic factors underlying them. Variants in over 30 different genes have been 
associated with different primary and secondary forms of NS (Table 1). 
However, only a portion of NS cases have determined causative factor; the 
majority remain unclear. 
 
 
Table 1  The proteins and genes variants in which lead to NS 
 Protein Gene Condition Inheritance Histology Reference 
Nephrin NPHS1 CNF, SRNS AR Microcystic tubule 
dilation, progressive 
MS (CNS), MPGN, 
MCD, FSGS (SRNS) 
 (87) 
Podocin NPHS2 SRNS, CNS AR FSGS, MCNS (148) 
PLCe1 PLCe1 DMS, SRNS AR FSGS (149) 
CD2AP CD2AP SRNS AD/AR FSGS (150) 
SD related 
TRPC6 TRPC6 SRNS AD FSGS (151) 
a-actinin-4 ACTN4 SRNS AD FSGS (152) 
Inverted formin-2 INF2 SRNS AD FSGS (76) 
NMMHC-A MYH9 FSGS - FSGS (153) 
Arhgap24 ARHGAP24 SRNS AD FSGS (154) 
Non-muscle class I myosin 1e Myo1E SRNS AR FSGS (155) 
RhoGDP	   dissociation	  
inhibitor	  α	  
ARHGDIA	   CNS	   AR	   DMS	   (156)	  
Actin reg. 
Anillin	   ANLN	   SRNS	   AD	   FSGS	   (157)	  
Integrin	  α3	   ITGA3	   CNS,	   interstitial	   lung	  disease,	  
epidermolysis	  bullosa	  
AR	   FSGS	   (158)	  
Integrin	  β4	   ITGB4	   CNS,	   epidermolysis	   bullosa,	  
pyloric	  atresia	  
AR	   FSGS	   (159)	  
Basal	  
membrane	  
Epithelial	  membrane	  protein	  
2	  
EMP2	   SSNS,	  SRNS	   AR	   MCNS	   (160)	  
GBM Laminin β2 LAMB2 Pierson’s syndrome AR DMS, FSGS (123) 
WT1 WT1 Denys-Drash, Frasier, SRNS AD, AR DMS, FSGS (73, 161) 
LIM homeobox transcription 
factor 1b 
LMX1B Nail-Patella syndrome AD FSGS (162, 163) 
Transcription 
factors 
SMARCA-like protein SMARCL1 Schimmke immuno-osseus dysplasia AR FSGS (164) 
tRNA_LEU MTTL1 MELAS ? FSGS (165) 
COQ6 COQ6 SRNS, sensorineural deafness AR FSGS (166) 
Parahydroxybenzoate-




Prenyl diphosphate synthase 
subunit 2 PDSS2 
CoQ10 deficiency/Leigh 
syndrome AR FSGS (168) 
Lysosomal integral membrane 
protein type 2 SCARB2 Action myoclonus-renal failure AR - (169) 
Zinc metallo-proteinase 
STE24 ZMPSTE24 Mandibuloacral dysplasia AR - (170) 
? GMS1 Galloway-Mowat syndrome AR DMS, FSGS (171) 
Phosphomannomutase 2 PMM2 Congenital defects of glycosylation AR 
Collapsing 
glomerulopathy (172) 
b-1,4-mannosyltransferase ALG1 Congenital defects of glycosylation AR FSGS (173) 
GLEPP1 PTPRO SRNS AR FSGS (174) 
Others 







Congenital nephrotic syndrome of the Finnish (CNF, NPHS1) type is a rare 
hereditary pediatric disease that is more common in Finland than elsewhere, 
with a frequency of approximately 1 in 8200 live births. Around the world, small 
populations exist where the disease has even higher frequency. For example 
among a subgroup of old order Mennonites in Lancaster County, Pennsylvania 
the frequency rises to 1 in 500 (176). 
 
CNF is characterized by massive proteinuria already in utero and severe 
nephrotic syndrome after birth. The disorder develops to end-stage renal 
disease (ESRD) very early in life and is lethal without intervention. No 
medicinal cure exists, although symptoms may be alleviated with albumin 
infusions that are commenced daily. In Finland, bilateral nephrectomy is 
carried out when the child weighs 7 kg, followed by dialysis. Renal 
transplantation is performed when the patient weighs approximately 10 kg and 
is 1-2 years old (177, 178). 
 
CNF follows AR inheritance pattern and is caused by mutations in the key SD 
component nephrin, encoded by NPHS1, which is a large gene of 26kb and 29 
exons located at chromosome 19q13.1. More than 200 different mutations have 
been reported worldwide, while in Finland 97% of all cases are caused by two 
particular mutations, Fin-major and Fin-minor (87). Sixty percent of the 
Finnish patients are homozygous for Fin-major, a deletion of two nucleotides in 
exon 2 (c.121_122delCT) that leads to a premature stop-codon and truncated 
protein product of only 90 amino acids instead of the 1241 amino acids of the 
healthy protein. Fin-minor is a nonsense substitution in exon 26 that leads to a 
stop-codon and truncated protein of 1109 amino acids (c.3325C>T). The other 
disease-causing mutations in CNF show great diversity as they include 
insertions, deletions, nonsense, missense and splicing mutations. While NPHS1 
mutations are predominantly associated with CNF, recent studies have 
identified certain specific, less severe mutations in patients with FSGS and 
disease onset at childhood or even adulthood (179).  
 
Reports show that many of the nephrin mutations, including Fin-major and 
Fin-minor, lead to total absence of nephrin from the SD (85). This is due to the 
damaged protein getting caught by the cellular quality control mechanisms at 
the endoplasmic reticulum. This mechanism plays an interesting, integral role 
in the development of the severe and quite homogenous disease phenotype of 
CNF caused by variety of different type of mutations, some leading only to 




1.3.2 SRNS  
 
Steroid resistant nephrotic syndrome (SRNS) accounts for approximately 15% 
of childhood primary NS globally (180). Typically SRNS is associated with FSGS 
in light microscopy (181). Electron microscopy (EM) shows foot process 
effacement as well as loss of foot processes even in the nonsclerotic areas. Loss 
of podocytes is reported in some adult SRNS patients. Clinical features of SRNS 
include proteinuria, hypertension and progression to ESRD. It is notable, 
however, that due to the great etiological heterogeneity behind SRNS 
considerable variability also exists in its clinical manifestations. As SRNS often 
progresses to ESRD bilateral nephrectomy and renal transplantation (KTx) is 
required. In a subset of approximately 33% of the patients the disease recurs 
after transplantation (182).  
 
There are idiopathic and familial forms of SRNS. While the majority of 
causative factors behind idiopathic SRNS remain unknown, approximately one 
third of cases have an underlying genetic injury that plays a role in the 
pathogenesis of the condition. The lower the age of onset the more likely it is 
that a causative variant can be found (183-185). Typically, cases where a genetic 
injury can be found run a lower risk of recurrence after KTx. Familial SRNS may 
follow either AR or AD inheritance pattern. AR form of the disease often has 
lower age of onset and more severe course of disease than AD form of the 
disease, which may manifest only in adulthood. A majority of the genes mutated 
in SRNS code proteins expressed in podocyte foot processes. 
 
Mutations in NPHS2, coding for podocin, lead to AR SRNS and are found in 12-
17% of sporadic cases (180). NPHS2 mutations are the most common genetic 
cause of SRNS identified in European patients. The 25kb NPHS2 is located on 
1q25-31 and consists of eight exons. Over a hundred disease-causing mutations 
have been found across the whole length of the gene. SRNS caused by 
homozygous or compound heterozygous mutations has a quite aggressive 
course with onset before six years of age and progression to ESRD during first 
decade of life. Different types of mutations may lead to variance in disease 
phenotype. Complete loss of podocin function may alter glomerular 
development and lead to CNS (186, 187). Mutations in C-terminus of the 
podocin, such as the common European mutation p.R138Q, lead to its retention 
in the endoplasmic reticulum of the podocytes and inability to take its place in 
the plasma membrane (188). As podocin plays a role in anchoring other 
proteins, including nephrin, CD2P and TRPC6, to the correct position in the 
membrane, retention of podocin may lead to their mislocalization as well. Other 
mutations are reported to induce podocyte apoptosis instead (188).  
 
Variant p.R229Q has unclear effect on podocin function but it does affect the 
disease phenotype as patients with heterozygotic p.R229Q together with 
another pathogenic variant in heterozygotic state lead to significantly higher age 
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of onset. As healthy individuals have been reported to carry homozygous 
p.R229Q, it either is not a pathogenic variant itself, or has an incomplete 
penetrance. One study suggested that the variant is not disease causing, but a 
modifier of variants in other genes (189). Another study reported that p.R229Q 
is only pathogenic when it is in a compound heterozygotic state with a 
pathogenic variant located in the exons 7 or 8 (190).  
 
Mutations in several genes coding for protein associated with actin-cytoskeleton 
have been discovered in patients with SRNS. While the precise functional effects 
of most of the mutations are not yet known they may affect the ability of the 
cytoskeleton to dynamically respond to changes in pressure of the capillary 
walls (191). CD2AP forms a link between SD and the actin cytoskeleton and 
mutations in it have been reported in few human patients. Heterozygous 
mutations cause sporadic SRNS with age of onset between 2-23 years while the 
one patient with homozygous CD2AP mutation reported so far suffers from 
more severe infantile form of NS (192-194). Similar pattern is seen in mouse 
models where CD2P-/- knockouts die at six weeks of age, while CD2AP+/- 
manifest proteinuria at nine months of age and generally exhibit similar 
pathology to human SRNS (150, 193) 
 
Missense mutations in ACTN4 gene coding for α-actinin-4 are associated with 
incompletely penetrant and late-onset AD SRNS (152). ACTN4 mutations in 
SRNS are only found in 4% of patients with familial SRNS (195). The identified 
mutations are clustered in the actin-binding domain resulting in increased 
binding to filamentous actin and formation of protein aggregates in vitro (196, 
197). In addition to affecting the cytoskeleton, a mouse model with ACTN4 
mutation K255E developed FSGS and activated the endoplasmic reticulum 
stress response, which results in expression of pro-apoptotic proteins and leads 
to possible cell death (198, 199). 
 
Mutations in INF2 cause 17% of AD SRNS but are rarely associated with 
sporadic cases (76, 77, 200). INF2 mutations are also found in patients with 
Charcot-Marie-Tooth disease and glomerulopathy (201). INF2 interacts with 
members of diaphanous formin subfamily of actin-regulating proteins (mDias). 
MDias have formin homology domains that are sites for actin nucleation and 
polymerization. They also have two regulatory domains: diaphanous inhibitory 
domain (DID) and diaphanous autoregulatory domain (DAD). In the absence of 
member A of Ras homolog gene family (RHOA), DID and DAD interact to 
inhibit actin polymerization. INF2 also has DID and DAD domains and INF2-
DID can also bind mDia-DAD and thus modulate mDias potential for actin 
polymerization (202, 203). Majority of described INF2 variants are 
heterozygous missense mutations clustered in the exons 2-4, which code for the 
N-terminus of the DID domain. The mutations may damage the inhibitory 
function of DID domain and result in overactivation of mDias and unbalanced 




Homozygous mutations in ARHGDIA, coding for RHO GDP-dissociation 
inhibitor 1, a regulator of GTP/GDP binding RHO GTPases, have recently been 
found in an infant with CNS and two siblings with early onset SRNS (204). In 
podocyte culture, wild type ARHGDIA binds RHOA, RAC and CDC42 and 
inhibits cell migration (204). Mutated ARHGDIA increases RAC1 and CDC42 
activity in vitro (204). 
 
Mutations in TRPC6 cause AD FSGS. Studies suggest that disease-causing 
mutations result in overactivation of the channel (151, 205, 206). This theory is 
supported by a study finding overexpression of TRPC6 in mice with FSGS (207). 
One possible mechanism for this route to podocyte injury is that TRPC6-
mediated calcium influx plays a role in mechanosensation. Increased calcium in 
the cell activates RHOA and thus affects the actin polymerization of the 
cytoskeleton as well as downregulate nephrin expression (208).  
 
Mutations in phospholipase C epsilon 1 (PLCE1) result in early onset SRNS and 
the quality of the mutation is reported to affect the disease phenotype as 
patients with truncating mutations showed histological lesion of diffuse 
mesangial sclerosis (DMS) while those with missense mutations had FSGS 
(149). In a mouse model, while PLCE1 knockout had no renal phenotype, 
enhanced PLC-family signaling lead to podocyte injury and proteinuria (149, 
209). PLC- family catalyzes the generation of second messengers to trigger the 
release of ER’s calcium storage pool and activate TRPC6 and thus increase the 
calcium influx in the cell (209, 210). PLCE1 may also play a role in podocyte 
differentiation and regulation of actin cytoskeleton and is associated with the 
SD components such as nephrin and podocin (149, 211, 212). 
 
In addition to proteins involved with SD and actin cytoskeleton, and their 
regulation, other podocyte-expressed proteins may be injured by genetic 
mutation in SRNS patients. Mutations in glomerular epithelial protein, GLEPP-
1, located at the apical membrane, cause AR SRNS (174). Wilms’ Tumor 1 (WT1) 
is a transcription factor that is essential for the renal development and 
differentiation. Mutations in WT1 cause Denys-Drash and Frasier syndromes as 
well as isolated NS (161, 213). Mutations in LIM homeobox transcription factor 
LMX1b are behind rare AD disorder Nail-Patella syndrome (214). Both of these 
transcription factors are also involved in the regulation of SD proteins. 
Mutations in lysosomal protein SCARB2 are found in AR myoclonus-renal 
failure syndrome (169) while mitochondrial gene MT-TL1 (coding leucine 
tRNA) mutation causes SRNS and respiratory chain defect (215). 
Apolipoprotein L1 mutations have been identified in African American patients 






Steroid sensitive nephrotic syndrome, SSNS, is the most common form of NS in 
children. It usually first manifests at 2-6 years of age and is twice as likely in 
boys than in girls. It is characterized clinically by a rapid onset of edema. Most 
often urinanalysis reveals only proteinuria but some patients may have hyaline 
or waxy casts and hematuria. While SSNS is usually associated with minimal 
changes in the glomerular structure in light microscopy, electron microscopy 
reveals foot process effacement, fewer SDs and reduction in slit pore size (217).  
 
SSNS is less severe than other forms of childhood NS as 85% of patients recover 
in four weeks of corticosteroid medication. However, SSNS has a tendency to 
run a relapsing course: about 80% patients have more than one episode and, of 
those who relapse, approximately half have frequent relapses (more than two 
relapses in six months or more than four in any one year) or become steroid-
dependent (two consecutive relapses during the corticosteroid treatment or 
within 14 days after its cessation) (218, 219). SSNS may be complicated by 
infections due to immunosuppressive therapy and thrombosis caused by 
combination of relative hypovolemia and hypercoagulable state (220).  
 
The etiology of SSNS is still not well understood although several avenues have 
been researched. Popular proposition is that SSNS has an immunological 
component as it is associated with abnormal T-cell response and often appears 
together with disorders with immunological base, such as atopy, autoimmune 
diseases and lymphomas (146, 221-223). It also often first appears after an 
infection although the mechanism of this is not known. Recently, especially 
respiratory tract virus infections are implicated (224, 225). T2-helper cell 
activation and production of cytokines such as IL4 and -13 (IL4 and IL13) that 
occurs in allergy, also occurs in animal models of SSNS (226, 227). However, a 
direct link between immune system and SSNS is yet to be found. On glomerular 
level, loss of GBM charge has been reported in some patients (228, 229). 
 
An interesting recent entry for causative component in SSNS is angiopoietin-
like-4 (ANGPTL4). ANGPTL4 is expressed in several tissues, among these the 
podocytes, although in a low level in normal state. In a rat model podocyte-
specific overexpression of ANGPTL4 leads to features similar to human SSNS: 
albuminuria, foot process effacement, responsiveness to steroids, as well as 
reduced charge in the GBM (230). As podocyte-secreted ANGPTL4 binds to the 
GBM and possibly reduces its charge, its binding sites in the GBM are clustered 
to areas that show foot process effacement, and glucocorticoid (GC) treatment 
reduced its expression significantly, Clement et al. suggested the protein plays a 
significant role in the development of SSNS (230). It is yet to be discovered if 




As a significant proportion of SRNS patients carry mutations in genes coding for 
podocyte proteins, these genes are of interest also in SSNS patients. As SSNS is 
a complex trait it is not likely that a single gene variants would have such an 
effect as in SRNS, but genetic variants may still have a role in the pathogenesis 
of disease, causative or modifying. So far, genetic findings in SSNS are scarce. A 
report by Hinkes et al. (149) found two patients with AR NS and mutations in 
PLCE1 gene (coding for 1-Phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase epsilon-1), one of which responded to cyclosporin and the 
other to corticosteroids. Interesting new candidate is epithelial membrane 
protein two (EMP2). Gee et al. (160) found recessive variants in its coding gene 
in three SSNS patients from two families. EMP2 is exclusively expressed in 
glomeruli and in knockdown mice without any EMP2 expression podocytes 
exhibited increase in CAVEOLIN-1, which is partially located in the SD. The 
particular connection between EMP2 variants, CAVEOLIN-1 and SSNS requires 
more investigation. 
1.3.3.1 Genetics of steroid sensitivity 
 
An essential question in NS treatment is to find reliable markers that predict the 
patient’s response to steroid medication. Existence of pathogenic variants in 
genes coding for podocyte proteins is thought to be a good indicator of steroid 
resistance although a few exceptions are found as previously mentioned. 
However, use of these variants as predictors can be onerous as the number of 
potential genes and variants continues to increase, even though developing 
techniques ease the burden. More eminent problem is that pathogenic variants 
are not found in all patients. Other predictors are required and the genetics and 
pharmacokinetics of steroid responsiveness are still insufficiently understood. 
 
A key component in the effectiveness of GCs is the glucocorticoid receptor (GR). 
In its inactive state GR is involved in multiprotein complex which, upon binding 
the GC breaks down. The active GR is transported in the nucleus where it 
undergoes dimerization, binds specific DNA sequences, the glucocorticoid 
response elements, and as a monomer, interacts directly with other 
transcription factors such as nuclear factor kappa B (231-233). Binding of GR to 
glucocorticoid response elements leads to increased activation of genes coding 
for anti-inflammatory proteins, such as interleukin-10 and inhibitor of nuclear 
factor kappa B (232). GR is coded by nuclear receptor subfamily 3, group C 
member 1 (NR3C1) and the involvement of several of its polymorphisms with 
idiopathic NS (INS) and steroid responsiveness has been studied (233-235). 
Curiously, while some polymorphisms were associated with reduced GC 
sensitivity, others lead to its increase (233, 234, 236, 237) 
 
Pro-inflammatory cytokines may also be involved in the formation of the GC 
response. One such cytokine is macrophage migration inhibitory factor (MIF). 
MIF is expressed mainly by T-cells but also by epithelial and endothelial cells in 
several tissues, including the podocytes (238). It is involved in securing innate 
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immune resistance of the organism but, as the range of action of the cytokines is 
broad, it is also a mediator in many inflammatory and autoimmune diseases, 
such as septic shock, ulceratis colitis, pneumonia, tumors and 
glomerulonephritis (239-241). While cytokines in general are suppressed by 
GCs, MIF interestingly seems to be induced by GCs and leads to inhibition of 
their activity (241, 242). Thus, therapies aiming at inhibition of MIF may be a 
potential way of enhancing corticosteroid responsiveness. Several polymorphic 
variants in MIF gene have been analyzed in many related diseases, including in 
NS. The minor allele in SNP −173G/C (rs755622) in MIF gene promoter was 
shown to be more frequent in steroid resistant patients (239, 240, 242). 
 
Rather new, potential target in association with steroid responsiveness is 
glucocorticoid-induced transcript 1 gene (GLCCI1), which is involved in steroid 
resistance in asthmatic patients (243). GLCCI1 is expressed in podocytes and 
knockout mice develop podocyte injury and proteinuria (244). Analysis of the 
asthma-associated SNPs has been carried out in Korean NS patients but no 
involvement was observed (245). The cellular role of GLCCI1 is yet to be 
clarified. 
 
P-glycoprotein (P-gp), coded by multidrug resistance gene MDR1, is a 
transporter of xenobiotics involved in elimination and intracellular 
concentration of many drugs including corticosteroids. Wasilewska et al. (246) 
measured P-gp expression in CD3 leukocytes in peripheral blood and found that 
SSNS patients had increased expression compared to healthy controls during 
relapses (before, during and 2 months after corticosteroid treatment), and the 
expression level was comparable to the corticosteroid dosage. P-gp expression 
level in the lymphocytes was also found to be significantly elevated in frequently 
relapsing and steroid-dependent patients compared to infrequently relapsing 
(247). Several studies have looked into the association of MDR1 polymorphic 
variants and NS as well as steroid responsiveness and found three variants 
(G3435T, G2677T/A, C1236T) to be related to both NS and to steroid 
responsiveness (248-251). These variants are thought to be associated with 
enhancement in MDR1 expression.  
 
Other potential factors engaged in the development of steroid resistance include 
subfamily 3A of human cytochrome P450, which plays a significant role in drug 
metabolism (233, 251), as well as pro-inflammatory cytokine tumor necrosis 
factor-alpha and anti-inflammatory cytokines IL4 and IL6, variants in which 
correlate with NS and have a possible role in diagnosis of SRNS (250). 
 
1.4 Genetics and search for disease causing variants 
 
Genetics is a field of science concentrating on the study of genes and 
inheritability. Its range can vary from molecular, cellular, organism, family and 
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population to all the way to evolutionary but still the focal point of interest 
remains in the gene, and in the functional and structural variability of the gene 
(252). Genetics is classified under biology but combines multiple fields of life 
sciences and is closely interconnected also with information systems.  
 
The field of study was fathered in 1860s when Gregor Mendel published his 
study on the inheritance patterns of certain traits in pea plants and their 
mathematical description (252). Approximately a hundred years later, as a 
result of the work of numerous researches, it was concluded that DNA was the 
molecule responsible for the inheritance. However, only after the discovery of 
the first specific genetic mutations as causative factors underlying inherited 
diseases, has the field of study begun its remarkable rise in both popularity and 
significance. 
 
The toolbox of a current day geneticist is a large one, including animal models 
and variety of functional analyses, but in here I concentrate on the methods 
most relevant to this thesis, namely sequence analysis and determining disease-
causing variants. 
 
1.4.1 Single nucleotide polymorphisms 
 
Typically genomic variants fall into one of five classes: 1) Single nucleotide 
polymorphisms (SNP) where one nucleotide has been substituted with another, 
2) insertions and deletions, where one or more nucleotides have been added or 
omitted, 3) copy number variation (CMV), where the copy number of a given 
sequence increases or decreases, 4) inversion, where the given sequence is 
turned around in position and 5) translocation, where the given sequence is 
shifted to another position (253). Most abundant of the variants in the human 
genome is the SNP. There are 10 million SNPs with minor allele frequency 
higher than 1% making the SNP density approximately one in 300 nucleotides.  
 
Most commonly SNPs lie in the non-coding regions of the genome and they 
have poorly known effect on the phenotype. When SNPs lie in the coding 
regions, splice sites or in regulatory regions they may play an essential role in 
the forming of the varying inheritable traits that make an individual. These 
traits also include inherited diseases, such as CNF and SRNS.  
 
1.4.2 Linkage analysis and genome wide association analysis 
 
In the latter half of 20th century the genetic linkage analysis was the method of 
choice for searching regions of the genome linked to studied phenotype, i.e. 
inherited disease. Linkage analysis is based on the notion that the closer two 
genetic loci physically are, the more likely they are to be passed on to the next 
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generation together. The further away two loci are from one another, the more 
likely it is that recombination occurs between them separating alleles to 
different copies of a chromosome. Linkage analysis uses a map of genetic 
markers, short sequences with variable genotype and known physical location in 
the genome, to find regions where the marker genotypes are linked, inherited 
together, with the disease phenotype.  
 
Previously genetic markers were microsatellites, few base pairs long sequences 
repeated 5-50 times, but more recently SNPs have taken their place. While 
microsatellites are more informative markers, as a single microsatellite can have 
several different copy numbers in population compared to the typically biallelic 
SNPs, their frequency in the genome is much lower, and their genotyping is 
slower and not as readily adaptable to high-throughput analyses (254-257). 
 
When loci are inherited together more often than expected if the loci where 
independent, they are said to be in linkage disequilibrium (LD). A block of 
several marker genotypes showing LD is called a haplotype. When a specific 
haplotype segregates with the disease phenotype, the genes in the genomic 
region of the haplotype may be considered candidate genes for the disease. 
 
Linkage analysis is especially powerful when searching for candidate genes for 
rare monogenic diseases in family pedigree data, like for instance in the case of 
CNF (258). However, when studying complex diseases with common genetic 
variants of varying, modest effect influencing the phenotype, the method loses 
power. In these experiments, genome-wide association studies (GWAS) using 
SNP makers gained popularity. However, the rise of the whole-genome 
sequencing studies has found new applications for linkage analysis (259).  
 
GWAS is a case-control –study that analyses SNP genotype frequencies in these 
two populations. If some genotype is significantly more frequent in people with 
certain phenotype, the two are said to show association. The analysis is carried 
out using microarrays that contain up to millions of SNPs selected uniformly 
around the genome. To this date, thousands of GWAS studies have identified 
tens of thousands SNPs associated with numerous traits and diseases (260, 
261). 
 
A challenge with GWASs is that they often result in great number of associated 
SNPs, most of which are located in the non-coding region, and as the 
significance of a variant is expected to be modest, it is difficult to study the 
relevance of the results (262, 263). So far, this seems to be a bottleneck in 








Sequencing is a basic molecular biological method to define the order of the 
nucleotides in a specific DNA strand. Sequencing can be used for instance to 
determine variants in a gene of interest or in association with a disease 
phenotype. 
 
1.4.3.1 Sanger Sequencing 
 
The most widely used sequencing method in the past decades has been Sanger 
sequencing that is based on polymerase chain reaction (PCR), which uses DNA 
polymerase and free nucleotides to synthesize a new sequence complementary 
to a template DNA strand originating from a specific primer sequence. The key 
invention is to substitute a small portion of the nucleotides of the reaction with 
modified, unextendable, labeled nucleotides (264). This results in a collection of 
varying length sequences with a labeled nucleotide in the end. The sequences 
are then arranged by size in an electric field. The sequences float past a detector 
that records the label, which is used to compile the DNA sequence. 
 
Sanger sequencing is very good method when analyzing limited amount of 
sequences in a limited amount of samples.  It has been often used to as a second 
step after linkage analysis, to find variants in found genes of interest. However, 
after the sequencing of the human genome, the interest has shifted towards 
large scale sequencing experiments, such as whole genome sequencing and 
whole exome sequencing.   
 
For these Sanger sequencing is not efficient enough. The human genome 
sequencing project used Sanger sequencing and it took 12 years, cost nearly 3 
billion dollars and involved hundreds of researchers around the world (265, 
National Human Genome Research Institute, 
https://www.genome.gov/11006943/ (cited 2.6.2016)). Even though its 
efficiency has advanced since the early days of the Human Genome Project, 
genome wide Sanger sequencing is not feasible for practical use in most 
research laboratories or in diagnostic ones. For these applications, next 
generation sequencing was developed. 
 
1.4.3.2 Next generation sequencing 
 
The term ‘next generation sequencing (NGS)’ includes several technologies, 
such as sequencing-by-synthesis (266), sequencing-by-ligation (267) and ion 
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semiconductor sequencing (268). As the presently predominant technique in 
the field of medical genetics is sequencing-by-synthesis used by Illumina 
devices, it is the technique I will concentrate on in this chapter. 
 
Sequencing-by-synthesis method is developed from the Sanger sequencing and 
share many of its features. This method too uses DNA polymerase synthesis 
with unextendable, fluorescent nucleotides. A great difference is that in 
Sequencing-by-synthesis all of the nucleotides are modified, not only a small 
portion. 
 
The template strand is bound to a specific position on a glass slide.  On one 
glass over 250 million different templates can be bound. The DNA synthesis 
reaction occurs and one nucleotide is added to the strands to be synthesized. 
The slide is then photographed with microscopic imaging system and the color 
and intensity of the fluorescent dyes are registered. Then the newly synthesized 
nucleotide residues are converted to regular bases, and the slide is ready for the 
next round of synthesis and imaging.  After the last round, information from the 
collected images is gathered to compile a sequence complementary to the 
template. All the sequences of a sample are then matched to a reference genome 
to form a complete read of the genome. 
 
The obvious huge benefit of this technique is the amount of sequences that can 
be synthesized simultaneously. On this method, the one NGS machine can 
sequence the human genome in little more than one day (269).  Due to its 
efficiency and cost-effectiveness NGS is in use in clinical laboratories as well as 
in research. It is used for instance in carrier screening, fetal aneuploidy testing, 
rare disease detection and assessing the risk and existence of cancer (270-273). 
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2. Aims of the study 
 
The aim of this thesis was to study the genetic and cellular mechanisms 
underlying proteinuric kidney diseases steroid sensitive nephrotic syndrome 
(SSNS), steroid resistant nephrotic syndrome (SRNS) and congenital nephrotic 
syndrome of the Finnish type (CNF). The specific aims were: 
 
1. To study the predictive value of clinical features and podocyte protein 
coding gene variants in MCNS 
 
2. To study the association of SNP variants in functional kidney molecules 
and GC metabolism related genes to the severity of the INS phenotype 
 
3. To study the role of genetic variation in a Finnish cohort of patients with 
SRNS 
 
4. To study the effects of the absence of nephrin to the expression of key 




3. Material and methods 
 
3.1 Patients (I, II, III) 
 
The patients involved in this work were diagnosed at the University Hospitals in 
Finland between 1965 and 1981 (I), or after 1989 (III). Blood samples for 
genetic analyses were collected during routine check-ups, or on request in their 
local health centers. The nomenclature of childhood nephrotic syndrome (NS) is 
confusing due to the overlapping terms. Here, the terminology follows the 
praxis used in the original articles.  
 
Study I: The study population included 111 MCNS patients. This unselected 
cohort of patients represents the majority of children with NS diagnosed in 
Finland at the time. Most patients were enrolled in the International Study of 
Kidney Disease in Children and were treated by protocols still used in pediatric 
nephrology. Helsinki University Hospital served as the primary care unit for 
most of the patients. Long-term data were attained from 104 individuals. 
 
Study II: The study cohort included 100 INS patients of whom 83 were 
diagnosed between 1965-1981 at the Children’s Hospital, Helsinki University 
Hospital. These 83 were enrolled in the International Study of Kidney Disease 
in Children and were treated by protocols still used in pediatric nephrology. The 
remaining 17 patients were diagnosed more recently at the Children’s Hospital, 
Helsinki University Hospital, and were still children or adolescents; of them 
SNP genotypes were used in statistical comparison between INS patients and 
controls. A blood sample for DNA extraction was gathered from all. 
 
Study III: Two pediatric siblings with SRNS (Family AM) was the starting point 
of this study. Seven other family members in three previous generations were 
recruited. Of these, three were inflicted with SRNS. In addition to Family AM, 
the cohort included twelve pediatric patients with SRNS. Nine of the twelve 
patients showed FSGS histology and MCNS. The clinical course of the disease of 
these patients was variable. Two had neurological symptoms. 
	  
3.2 Kidney tissue samples (IV) 
 
The kidney tissue samples came from 20 children with CNF caused by Fin-Major and 
Fin-Minor mutations. The children underwent nephrectomy at the Children’s 
Hospital, Helsinki University Hospital as a part of the therapy. The 
nephrectomy was performed at the age of 6-8 months when the renal histology 
was still well preserved, showing little sclerotic changes. The CNF samples were 
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analyzed against control samples from 14 adult organ donors whose kidneys 
were unsuitable for transplantation but still showed normal histology.  
 
The kidney biopsy samples from 11 MCNS patients were collected by core needle 
biopsies performed on clinical grounds. Patients were divided into two 
categories, those with proteinuria at the time of the biopsy (n=5) and those in 
remission at the time of sampling (n=6). Control biopsy samples came from 
non-proteinuric pediatric patients (n=5) with kidney disorders including IgA 
nephropathy, Henoch-Schönlein purpura, benign hematuria, and post-infection 
nephritis.  
 
3.3 Data collection (I, II) 
 
Clinical data from all 104 patients were carefully recorded from the hospital 
records. The present health status was verified by mailed questionnaires and 
interviews performed at an outpatient clinic (40 subjects) or by phone (64 
subjects). The mean age at the last follow-up was 35.0 years (range 25.1–
44.1 years). The questions dealt with possible signs and symptoms of 
proteinuria or other renal manifestations in adulthood, family history, presence 
of any other diseases, regular medication, as well as the number of pregnancies 
and children. Whenever the information obtained from the questionnaire or the 
first telephone contact was inadequate, the participant was re-interviewed by 
phone. Also, data were received from the patient’s general practitioner or local 
hospital, when needed. Seventy-seven participants also visited the laboratory at 
Helsinki University Hospital or their local health centers. They were chosen 
based on the place of residence (the southern part of Finland) and had different 
clinical courses and outcomes. The features of the disease (number of episodes, 
duration of the disease) in these subjects represented well the whole group. 
Urinalysis was performed by dipstix, and plasma creatinine, albumin and 
cholesterol were measured in this subgroup. 
 
3.4 Immunostaining (III, IV) 
 
Antibodies used for immunofluorescence staining were goat polyclonal 
antibodies against ILK (C-19, sc-7516), Integrinα3 (I-19, sc-6592), LMX1β (N-
14, sc-21231) and Pod1 (P16, sc-15007), mouse monoclonal antibodies against 
Nck1/2 (G-12, sc-166425), Smad7 (Z8-B, sc-101152) and ZHX2 (Z-07, sc-
101562), and rabbit polyclonal antibodies against Fat1 (HPA023882), Neph1 
(H-150, sc-33136), WT1 (c-19, sc-192), ZO-1 (61-7300), podocin (C-18, sc-




Antibodies used for immunoperoxidase staining were mouse monoclonal 
antibodies against α-Actinin-4 (LW-M23, sc-134236), β-dystroglycan (4F7, sc-
33702), CD2AP (B-4, sc-25272), Fyn (FYN-59, sc-73388) and Podocalyxin 
(4F10, sc-23903), rabbit polyclonal antibodies against Nfκb(p50) (NLS, sc-114), 
N-WASp (H-100, sc-20770) and Pax2 (B24, sc-133889), and goat polyclonal 
antibody against podocin (N-21, sc-22294). 
 
All antibodies were manufactured by Santa Cruz (Santa Cruz Biotechnology, 
Santa Cruz, CA) except antibodies against Fat1 (Sigma-Aldrich Inc., St. Louis, 
Missouri, USA), ZO-1 (Invitrogen, Carlsbad, California, USA) and nephrin (by 
courtesy of Karl Tryggvason lab, Karolinska Institute, Stockholm, Sweden). 
 
Immunofluorescence staining of the kidney cryosections (5 µm) was carried out 
using a traditional protocol. Acetone fixing was applied. Sections used as 
negative controls were incubated in phosphate-buffered saline (PBS) instead of 
a primary antibody. Several secondary antibodies were used depending on the 
primary antibody.  
 
Immunoperoxidase staining was performed on sections of formalin-fixed, 
paraffin-embedded renal samples using NovoLink Polymer Detection System 
(RE7150-K, Leica Microsystems GmbH, Wetzlar, Germany) or ImmPRESS 
Anti-Goat Ig (peroxidase) Polymer Detection Kit (MP-7405, Vector Laboratories 
Inc., Burlingame, CA, USA). Reaction times were assessed for each antibody by 
using trial samples and then the same optimized reaction time was used for 
each patient and control sample to ensure comparable results. For each 
antibody, all samples were stained at the same time. 
 
3.5 Light microscopy (III, IV) 
 
Light microscopy was performed with a standard Leica DM RX light 
microscope. Each glomerulus was photographed separately under microscope 
and the image then imported to Apple Preview 5.0.3 (504.1) application for 
grayscaling. The semiquantitative scoring was carried out by defining specific 
staining in each glomerulus and then calculating the area fraction – the portion 
of specific staining in glomerulus versus background- using NIH ImageJ 1.32j 
(National Institutes of Health, Bethesda, MD, USA). Between 59 and 121 





3.6 Genetic analyses (I, II, III) 
 
Genomic DNA was isolated from frozen or fresh peripheral blood samples using 
the conventional molecular biology technique (Puregene EPTM DNA 
Purification Kit, Gentra Systems). The analyses of protein coding regions of 
NPHS1 (NM_004646), NPHS2 (NM_014625), NEPH1 (NM_018240), CD2AP 
(NM_ 012120) and ACTN4 (NM_004924), as well as exons 2 and 4 of INF2 
(NM_022489) were performed using direct sequencing. Exons were amplified 
by PCR with flanking intronic primers. The reactions were performed in total 
volumes of 25 µl as previously described by Lenkkeri et al. (316). Occasionally, 
the denaturation temperature was raised up to 98°C, or betaine was added to 
the reaction mixture. PCR products were subjected to automated sequence 
analysis by BigDye-terminator chemistry (v.3.1) on Genetic Analyzer 3730 
(Applied Biosystems). The sequences were analyzed with GeneComposer 
version 1.1.0.1051 (www.GeneComposer.com) or 4Peaks version 1.7.2 (by 
Griekspoor A and Groothuis T, mekentosj.com.). 
When a nucleotide change resulting in an amino acid change was spotted, the 
significance of the change was studied by sequencing the same exon from 23–51 
healthy controls except in the case of the deletion carried by Family AM (study 
III) which was checked from 101 healthy controls. Also, the healthy members of 
Family AM were sequenced as controls. 
In addition, Blueprint Genetics was commissioned to carry out a Nephrotic 
Syndrome sequencing panel of nine genes 
(http://blueprintgenetics.com/nephrotic-syndrome-panel/) to four healthy and 
three affected members of Family AM. While the panel included NPHS1, 
NPHS2, ACTN4 and TRPC6 that were previously sequenced it also contained all 
the rest of the INF2 exons as well as genes CD2AP, LAMB2, PLCE1 and WT1. 
The panel targets all exons, intron/exon boundaries and known mutations 
outside these regions.  
 
The effects of amino acid changes were evaluated by using online bioinformatics 
tools Predict Protein server, Prosite database and PolyPhen. 
 
Whole genome sequencing (WGS) method was used to analyze the sequences of 
the coding and non-coding areas of NPHS2, NPHS1, INF2, CD2AP, WT1, 
TRPC6, ACTN4 and PLC1. The experiment was carried out in two affected (II-1 
and IV-2) and two healthy (I-1 and II-2) members of the family AM in the 
Finnish Institute of Molecular Medicine (www.fimm.fi, University of Helsinki, 
Biomedicum, Helsinki Finland). The whole genome sequencing data analysis 





3.7 Single nucleotide polymorphisms (II) 
 
We selected eleven SNPs from eight genes to this study based on previous 
reports in literature on their association with INS. The genes and SNPs were 
Angptl4 SNP rs1044250 (c.797C>T), GPC5 SNP rs16946160 
(c.325+102637G>A), IL-13 SNP rs848 (c.*526C>A), MIF rs755622 
(c.−270G>C), nNOS rs2682826 (c.*276C>T), MDR1 SNPs rs1128503 
(c.1236C>T), rs2032582 (c.2677G>T/A), rs1045642 (c.3435C>T), GLCC11 SNPs 
rs37972 (c.-1473C>T) and rs37973 (c.-1106A>G) and NR3C1 rs41423247 
(c.1184+646G>C).  
 
3.8 Plasmids (III) 
 
Wild type (WT) and c.988_989delCT -mutated NPHS2 sequences were inserted 
to pCMV-Myc –vector (Clontech, Palo Alto, CA, USA) to give them N-terminal 
Myc-tag. The WT-NPHS1 was inserted to pcDNA3.1 –vector (Invitrogen, 
Carlsbad, CA, USA). Plasmids were amplified using JM109 competent E.coli 
cells, QIAGEN Plasmid Maxi Kit (QIAGEN inc. Valencia, CA, USA) and the 
protocol provided by the kit. 
 
3.9 Co-immunoprecipitation of nephrin and podocin (III) 
 
HEK293FT cells were transiently transfected with two plasmids: one carrying 
WT-nephrin, the other carrying either WT-podocin or c.988_989delCT -
mutated podocin. The transfection was carried out using FuGENE 6 –protocol 
(Roche, Basel, Switzerland). After incubating for 24 hours the cells were washed 
in PBS and lysed in non-denaturing lysis buffer containing 20 mM TrisHCl 
pH8, 139 mM NaCl, 10% glycerol, 1% NP40, 2 mM EDTA, and phosphatase and 
proteinase inhibitors. Cell lysates were incubated with c-Myc (A-14) antibody 
(Santa Cruz Biotechonology Inc., Santa Cruz, CA, USA) over night at +4°C on 
gentle agitation. After this, 50 µl 50% rec Protein G-Sepharose beads 
(Invitrogen, Carlsbad, CA, USA) were added to the antibody-protein complex 
mix and incubated over night at +4°C on gentle agitation to bind the antibody to 
the beads. Beads were washed with the lysis buffer and fractioned by SDS-
PAGE. Western blot analysis was performed using nephrin antibody (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA) followed by the incubation with 
horseradish peroxidase-coupled anti-goat antibody. Immobilized antibodies 




3.10 Data analysis and statistics (I, II, IV) 
 
The statistical examination of the data was carried out with statistical software 
JMP 9 and 10 (www.jmp.com, SAS Institute Inc., Cary, NC, USA).  
 
Study I: Logistic regression analysis was used to calculate odds ratios (OD) and 
95% confidence intervals (CI) for the effects of each predictor variable on these 
outcomes. T-test was used to compare background clinical data between groups 
(Mann Whitney in the case of non-normally distributed variable). 
 
Study II: Logistic regression analysis was used to calculate odds ratios and 95% 
CI for the association between genotypes and the risk of INS. The difference 
between selected clinical variables and genotypes was determined by Fisher’s 
exact test. 
 
Study IV: Data are presented as a median with interquartile range (IQR). The 
differences between control and CNF patients were evaluated using Mann-
Whitney-Wilcoxon test. All figures were composed using Adobe Photoshop CS3 
imaging software (http://www.photoshop.com/). 
 
P-values < 0.05 were considered significant.  
 
3.11 Ethics (I, II, III, IV) 
 
All patients or their parents were informed of the content of the study and they 
signed a form of consent. The study was approved by the Ethics Committee of 
the Children’s Hospital, Helsinki University Hospital. 
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4. Results  
 
4.1 Clinical characteristics of childhood MCNS (I) 
 
4.1.1 Clinical features of childhood MCNS 
 
The clinical features of the 104 analysed patients are summarized in Table 2. 
Twenty-three patients had only one episode of nephrotic range proteinuria 
while a majority of the patients relapsed during childhood (81 patients, 78%). 
The amount of relapses showed considerable variation (range 1–28 relapses, 
median 3). Fourteen patients (13.5%) continued to suffer from proteinuria in 
adulthood. Three of them had occasional mild proteinuria while three had 
condition severe enough to cause constant proteinuria and were under 
continuous corticosteroid medication. Eight of the fourteen had a mean number 
of 1.9 nephrotic episodes in adulthood (range 1–4 years). The period between 
the childhood and adulthood episodes varied (range 2-17 years) and the mean 
interval between episodes in adulthood was 4.6 years (range 1–11 years). None 
of the patients developed renal failure. 
 
4.1.2 Long-term outcome of childhood MCNS 
 
The interviews revealed that the general health of the participants was good in 
adulthood. None had lymphomas or other types of cancer. One participant was 
treated for hypercholesterolemia. Seventeen percent reported some allergic 
problems, mainly hay fever, which is in accordance with their prevalence in the 
Finnish population. The prevalence of diabetes (4.2%), asthma (6.7%) and 
ulcerative colitis (2.9%) was slightly elevated from the prevalence in the Finns of 
similar age (the respective figures: 2.5%, 4.1% and 0.4%; statistics of the 
National Public Health Institute, Helsinki, Finland). One participant had both 
diabetes and ulcerative colitis and one had a combination of diabetes, ulcerative 
colitis and psoriasis.  
 
4.1.3 Clinical Predictors in MCNS 
 
Severe course of the disease was not associated with analysed features such as 
mesangial hypercellularity in kidney biopsy, male sex, and young age of onset. 
No association between autoimmune disease in adult life and severity of 
childhood MCNS was observed. However, subjects with adulthood proteinuria 
had a tendency for a complicated disease already in childhood. These 
complications included a higher number of childhood episodes (mean 15.6 vs. 
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4.9 episodes, OR for each additional episode 1.19 (95% CI 1.10 to 1.30), P 
<0.0001), more frequent steroid dependency (57% vs. 10%, OR 12.0 (3.4 to 
42.4), P =0.0001) and need for cytostatic drugs more often (71% vs. 35%, OR 
3.9 (1.1 to 13.5), P =0.03) as compared to those with episodes only in childhood. 
None of the parents, siblings or offspring of the study subjects had nephrotic 




Table 2 The clinical characteristics of the kidney disease in the study cohort 
Characteristics Patients 
 N=104 
 Males (%) 74 (71) 
Age and Duration (mean (range))  
 Age at last follow-up in years 35.0 (25.1-44.1) 
 Follow-up time in years 30.0 (20.8-37.9) 
 Age at onset of MCNS in years 5.0 (0.65-13.1) 
 Duration of the disease in years 4.6 (0.1-33.4) 
Biopsy (%) (n=86)  
 No/minimal changes 69 (80) 
 Mesangial hypercellularity 17 (20) 
Childhood episodes (%)  
 One episode 23 (22) 
 2-5 episodes 46 (44) 
 6-10 episodes 16 (15) 
 >10 episodes 19 (18) 
 Frequent relapses 54 (52) 
Adulthood episodes (%)  
 Nephrotic episodes 11 (11) 
 Temporary proteinuria 3 (2.9) 
Medication (%)  
 Steroid dependency 17 (16) 
 Cytotoxic therapy 45 (43) 
 Steroid treatment at the last follow-up 5 (4.8) 
 
4.2 Genetic variation in INS (I, II, III) 
 
4.2.1 Variants in podocyte protein coding genes in MCNS 
 
No homozygous missense or nonsense variants were found in the direct 
sequencing of genes coding for the four slit diaphragm proteins nephrin, 
podocin, Neph1 and CD2AP of the 38 MCNS patients. CD2AP was highly 
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conserved, and not even synonymous changes were uncovered. Similarly, 
NEPH1 had no amino acid changing variants, and only three synonymous 
substitutions in exons 4, 8 and 13. In the NPHS2 gene p.E87K variant was found 
in one patient, and not in the controls. Heterozygous variant leading to p.R229Q 
was detected in four MCNS patients (11%) and in five of the 51 controls (10%). 
In addition, five synonymous substitutions were found in the NPHS2 gene both 
in the study subjects and in controls. 
 
NPHS1 had more genetic variation. Seven out of the 38 patients (18%) had nine 
heterozygous variants leading to amino acid changes. None of these were found 
in controls. Five synonymous substitutions were detected both in MCNS 
patients and in controls. 
 
The analysis included three patients with proteinuria in the first degree relative. 
One patient, whose father and brother had proteinuria but no nephrotic 
episodes, had p.T291 amino acid substitution in nephrin and p.R229Q 
substitution in podocin. The second patient, whose mother had temporary 
proteinuria, had heterozygous p.R800C in nephrin. The third patient, whose 
sister had temporary proteinuria, had only known benign polymorphic changes 
in nephrin and podocin genes. 
 
Also, the analysis included nine subjects with adulthood proteinuria and three 
of them had mutations in nephrin or podocin genes. One had the Fin-major 
deletion and a missense mutation leading to p.R800C in the nephrin gene. His 
proteinuria in adulthood was temporary without clinical manifestations. In the 
laboratory control, his plasma creatinine level was little elevated (1.43 mg/dl; 
GFR 80 ml/min/1.73m2). No biopsy findings were available. The second patient 
had a single amino acid change in nephrin (p.S1058L). The third patient had 
two amino acid changes in nephrin (p.S786N and p.G879R) and 1 substitution 
in podocin (p.E87K). Table 3 summarizes the found amino acid changing 
variants and the clinical features of their carriers. 
 
4.2.2 Variants in podocyte protein coding genes in Finnish pediatric 
SRNS 
 
We carried out direct sequencing exons and exon/intron boundaries of NPHS1, 
NPHS2 and NEPH1 in a cohort of Finnish pediatric patients with sporadic 
SRNS. This analysis showed very little variation. One of the twelve sporadic 
SRNS cases in the study had an amino acid changing variants in NPHS2, 
p.P341R in one allele and p.R229Q in two alleles. SRNS was diagnosed in this 
patient at the age of six and she is now waiting for the kidney transplant at the 
age of 19 years. In the NPHS1 gene, six of the twelve patients had one or more of 
three known amino acid changing polymorphisms (p.E117K, p.R402Q, 
p.N1077S), which were also displayed in the healthy controls in similar 
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frequencies. No patient carried amino acid changing variants in the NEPH1 
gene. A few synonymous substitutions were detected in all three genes. 
 
 
Table 3 The number of NPHS1 and NPHS2 variants leading to amino acid substitution 
and clinical manifestations of the patients carrying them. 
Subjects with <5 relapses in 
childhood 
n=12  
No Changes 8  
Amino Acid substitutions:   
NPHS1 2 1 patient with a NPHS1 and NPHS2 variants 
NPHS2 3  
Subjects with 5-16 relapses in 
childhood 
n=6  
No Changes 5  
Amino Acid substitutions:   
NPHS1 1  
NPHS2 0  
Subjects with slow response to GC 
treatment or GC dependency 
n=11  
No Changes 9  
Amino Acid substitutions:   
NPHS1 1 2 variants in one subject 
NPHS2 1  
Subjects with proteinuria in 
adulthood 
n=9  
No Changes 6  
Amino Acid substitutions:   
NPHS1 3 2/3 subjects had two variants 
NPHS2 1  
	  
4.2.3 SNPs in INS 
 
We compared the frequencies of eleven SNPs in eight genes between INS 
patients and controls, as well as between subgroups of INS patients.  
 
The clinical variables in the analysis included: age of onset (< 3 yr vs. > 3 yr), 
number of relapses (<5 vs. >5), frequent relapses (no vs. yes), response to 
glucocorticoids (GC) (normal vs. slow/no response), and treatment (only GC vs. 
GC together with immunosuppressive drugs (IS)). Notably, the majority of the 





4.2.3.1 Comparison between patients and controls 
 
Five SNPs from five genes encoding for functional kidney molecules and six 
SNPs from three genes involved in steroid metabolism were analysed from 100 
INS patients. The distribution of observed genotypes was consistent with those 
expected under the assumptions of the Hardy-Weinberg Equilibrium (p>0.05). 
 
No association between variant frequencies and disease status was observed 
except in rs848 variant in IL-13 gene, where patients and controls differed in 




Table 4 The associations of SNPs in functional kidney genes and their comparison to 
recent studies. 





Angptl4 rs1044250 (c.797 C>T) 	   	  
 Association with C allele and IS medication need 	   	  
GPC5 rs16946160 (c.325+1026376G>A)   
 Association of AA genotype with NS No Yes1 
 Association of A allele with disease onset Yes  
 A allele frequency 0.168 0.081 
IL13 rs848 (c.*526C>A)   
 Association of genotype distribution with long-term outcome No Yes2 
MIF rs755622 (-270G>C)   
 Association of C allele and/or GC genotype with NS No Yes3. Yes4. No5 
 Association of CC genotype with GC resistance No Yes3. Yes4. No22 
nNOS rs2662826 (c.*276C>T)   
 Association of TT genotype with NS No Yes6 
 Association of TT genotype with GC responsiveness No No6 
1 Okamoto et al. 2011 (175) 2 Wei et al. 2005 (274) 3 Berdeli et al. 2015 (239)  
 4Vivarelli et al. 2008 (240) 5 Choi et al. 2011  (249) 6 Alasehirli et al. 2009 (275) 
 
4.2.3.2 Functional kidney molecules 
 
The SNPs in the genes Angptl4, GPC5, MIF, nNOS and IL-13 encoding the 
functional kidney proteins revealed few statistically significant correlations to 
the clinical variables. IL13, MIF and nNOS showed none. In Angptl4 SNP 
rs1044250 the C allele was more frequent in patients who received other IS drug 
medication instead of GCs only (72 vs. 54%, p=0,0228). In GPC5, we observed 
an association between rs16946160 A allele and early disease onset (16 vs. 5%, 
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p=0,0421). The findings and their comparison to recent studies can be found in 
Table 4. 
 
4.2.3.3 GC metabolism related molecules 
 
Analysed genes included MDR1, NR3C1 GLCCl1. The genotype distribution in 
MDR1 SNPs showed difference in patients who received only GCs compared to 
those who also received other IS medication as allele T frequency was higher in 
the latter group in rs1128503 (70.6 vs. 28.6%, p= 0.0012), in rs2032582 (67.9 
vs. 42.9%, p= 0.0028) and in rs1045642 (73.1 vs, 52.4%, p= 0.0092).  
 
A curious finding was that NR3C1 SNP rs41423247 heterozygous GC genotype 
was more frequent in patients with more than five relapses (68 vs. 32.7%) and 
in patients with frequent relapses (60 vs. 34%) as well as in patients with severe 
course of the disease compared to those with milder course (63 vs. 34%). 
 
In GLCCI1 SNP rs37973 A allele was more frequent in patients who received 
other IS medication (67 vs. 50%, p= 0.0387). Patients with more than five 
relapses also had GLCCI1 SNP rs37973 A allele more frequently than those with 
fewer than five relapses (70 vs. 52%, p= 0.0377).  
 
The results and their comparison to recent studies can be found in Table 5. 
 
4.2.3.4 Haplotype analysis of MDR1 SNPs 
 
Summary of the haplotype analysis of the MDR1 variants rs1236, rs2677 and 
rs3435 can be seen in Table 6. The analysis revealed twelve estimated 
haplotypes in cases and controls. In patient samples the allele frequency of the 
two most common haplotypes, TTT and CGC, was 70% (42.2 and 27.5% 
respectively) while in the control samples it took four most common haplotypes, 
TTT, CGC, CTT, and TGT, to achieve the same (23.4, 18.6, 15.6 and 12.6% 
respectively).  
 
The distribution of the allele frequencies of the haplotypes showed significant 
difference between patients with less than five relapses and patients with more 
than five relapses (haplotype CTC frequencies 40.6 vs. 55.3%, respectively, p= 
0.04). In other variants, no statistically significant variation can be seen. In all 
variants, TTT and CGC haplotypes had the combined allele frequency varying 







Table 5 The associations of SNPs in GC metabolism related genes and their comparison 
to recent studies. 
Gene Found association Current 
study 
Referenced study 
MDR1 rs1128503 (c.1236C>T)   
 Association of T allele and/or TT genotypes with IS 
medication need 
Yes  
 rs2032582 (c.2677G>T/A)   
 Association of genotype distribution with NS No No1. Yes2. Yes3. No4 
 Association of CC genotype with age of onset No No1. No2. Yes3. No4 
 Association of T allele and/or TT genotype with GC 
responsiveness 
Yes  
 Association of T allelle and/or TT genotypes with IS 
medication need 
Yes  
 rs1045642 (c.3435C>T)   
 Association of T allele and/or TT genotype with NS  No Yes1. Yes2. Yes3. No4 
 Allele frequencies of controls (C/T. %) 37.2/62.8 45.2/54.81. 66.4/33.62. 58.5/41.53. 
42.0/58.04. 42.4/57.65 
 Association of CC genotype with age of onset Yes No1. No2. Yes3. No4 
 Association of T allelle and/or TT genotypes with IS 
medication need 
Yes  
 Haplotype    
 Association with GC responsiveness No Yes1. Yes3. Yes4. No5 
 Frequency of TGC haplotype (Case/Control. %) 4.2/7.8 1.1*1.8.3/6.52. 21.7/18.63. 21.2/184. 
1.1/2.35 
GLCCI1 rs37972 (c.-1473T>C)   
 Association of genotype distribution with GC 
responsiveness 
No No6 
 rs37973 (c.-1106G>A)   
 Association of genotype distribution with GC 
responsiveness 
No No6 
 Association of A allele with patients with more than five 
relapses 
Yes  
 Association of A allele with IS medication need Yes  
1 Wasilewska et al. 2007 (248) 2 Jafar et al. 2011 (250) 
3 Youssef et al. 2013 (276)  4 Choi et al. 2011 (249) 








Table 6  Most common estimated haplotypes in INS patients vs. controls and in patients with <5 






OR (95% CI) p 
 n (%) n (%)   
TTT 69 (42.2) 46 (23.4) 0.42 (0.27-0.66) 0.002* 
CGC 45 (27.5) 36 (18.6) 0.60 (0.36-0.98) 0.0412* 
CTT 13 (8.1) 31 (15.6) 2.18 (1.10-4.33) 0.0254* 
TGT 7 (4.5) 25 (12.6) 3.28 (1.38-7.79) 0.0072* 
CGT 11 (6.5) 20 (10) 1.58 (0.73-3.40) 0.242 
TGC 7 (4.2) 15 (7.8) 1.86 (0.74-4.67) 0.1877 
CTC 2 (1.3) 15 (7.7) 6.71 (1.51-29.80) 0.0123* 







OR (95% CI) p 
 N (%) N (%)   
TTT 42 (40.4) 28 (55.3) 1.88 (0.95-3.71) 0.04* 
CGC 32 (30.8) 16 (31.4) 1.06 (0.51-2.91) 0.88 
Other 30 (28.8) 6 (12) 0.19 (0.02-1.54) 0.1205 
 
 
4.3 Podocyte protein coding genes in Finnish familial SRNS (III) 
 
4.3.1 Rare clinical course of familial SRNS  
 
The first member of Family AM with NS is a daughter of healthy parents (II-1 in 
Figure 7). She was diagnosed by chance with proteinuria at the age of 18 in a 
routine check-up. As at that time she was symptomless it is impossible to say 
how long the proteinuria had continued. A kidney biopsy showed only minimal 
changes. However, a new biopsy taken seven years later when the patient was 25 
years old showed the tissue damage had progressed to FSGS. By this time the 
proteinuria had worsened significantly. The patient reached ESRD at the age of 
40 and received a kidney transplant a year later. The disease has not recurred 
after transplantation. 
 
The patient II-1 had two sons, both of whom were diagnosed with NS at young 
age (2,5 (III-2) and 1,8 years (III-3)). Both sons had only low level of proteinuria 
as a child but it worsened dramatically by the time they were young adults. The 
elder of the boys developed ESRD at the age of 25 and received a kidney 
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transplant at the age of 31. The younger son has not yet reached ESRD but in his 








The elder son has two daughters, both having proteinuria diagnosed soon after 
birth (IV-1 and IV-2). The elder of two is 12 years old and at the latest check-up 
her proteinuria had worsened but is still under 4 g/l. The younger is 3,5 years 
old and her proteinuria is still under 1 g/l. 
 
4.3.2 NPHS2 in the familial NS 
 
The gene sequence of NPHS2 was analysed in several ways. It was analysed 
using direct sequencing of exons and exon/intron boundaries, it was included to 
the NS gene panel that checked relevant intronic regions in addition to exon and 
exon/intron boundaries, and was thoroughly checked during WGS analysis that 
included all the intronic and control regions. 
 
Only one variant was found in NPHS2 that was carried by only the affected 
patients in the family and none of their healthy family members or unrelated 
controls. Neither was any combination of variants found that would have 










The variant that was found, a heterozygous two nucleotide deletion 
c.988_989delCT (Figure 8), is a de novo variant of the first affected member of 
the family (II-1) as the patient’s healthy parents do not carry the variant. Her 




Figure 8 The deletion c.988_989delCT of the Family AM. 
 
 
The c.988_989delCT affects the last 52 amino acids of the 384 amino acid 
protein podocin; amino acid 329 is followed by frame shift and premature stop 
codon 14 amino acid later. Thus, the NPHS with c.988_989delCT2 codes for 
p.L329fs*14 and leads to podocin protein that only has 343 amino acids.  
 
We studied the effects of c.988_989delCT to the function podocin and its 
expression in the kidney tissue. Immunofluorescence staining showed that 
while the patients in Family AM still expressed nephrin and podocin in their 
podocytes, the staining of nephrin was qualitatively altered and discontinuous, 
and the staining of podocin was much diminished (Figure 9A). Co-
immunoprecipitation experiment showed that truncated podocin binds to 
nephrin similarly to wild type podocin (Figure 9B). The Predict Protein revealed 
that the two- and three-dimensional structure of the podocin was not drastically 
altered by c.988_989delCT. Nine proline residues are lost by the truncation. 
 
4.3.3 Other podocyte genes in familial SRNS 
 
Possible variants causing the NS in Family AM were also searched for in other 
genes coding for podocyte proteins. We included genes variants in which are 
associated with dominantly inherited SRNS (ACTN4, INF2, TRPC6, WT1 and 
CD2AP) as well as genes associated with recessive SRNS and NS in mouse 
models (NPHS1, LAMB2, PLCε1 and NEPH1). 
 
Analysis of NPHS1, NEPH1, and ACTN4 using direct sequencing revealed only 
known polymorphisms. The nephrotic syndrome panel of Blueprint Genetics 
analysed genes CD2AP, WT1, LAMB2, TRPC6, PLCε1 and INF2 in addition to 
NHS2 and NPHS1, and did not find any variant in any gene that would have 







associated gene that was shared by the two affected family members included to 
the WGS analysis (II-1 and IV-2) but not the two healthy ones. Direct 
sequencing of this non-coding variant (a single nucleotide deletion 
(rs76500597) in WT) in the rest of the family members revealed no shared 
genotype between the affected individuals: one affected did not carry the 






Figure 9  Functional study of c.988_989delCT. A Expression of nephrin and podocin in 
normal human kidney (NHK), CNF and Family AM kidney. The biopsy section 
came from patient IV-1. 40x magnification. B Co-immunoprecipitation of WT-
podocin and c.988_989delCT-podocin with nephrin.  
 
4.4 Podocyte Proteins in kidney disease (IV) 
 
The expression of several proteins from different cellular compartments of podocytes in 
CNF was stained and analysed using Immunohistochemistry. The main findings are 
presented in Table 7 and in Figure 10. The expression of few key proteins were 




4.4.1 Podocyte proteins in CNF 
 
The expression of slit diaphragm proteins in the analysis was reduced in CNF 
glomeruli. While the Fat1 expression showed only moderate decrease (2,6-fold in area 
fraction) the expression of Neph1 was drastically diminished (45-fold). 
 
The expression of adaptor proteins was close to controls in the case of podocin and 
NCK1/2 (1,1-fold and 1,4.fold increase, respectively), and moderately increased in the 
case of CD2AP (3,3-fold). 
 
Actin cytoskeleton proteins ACTN4 and INF2 showed mildly increased staining (2.2-
fold and 1.7-fold, respectively) while N-WASp staining was not significantly altered. 
 
The staining for basal membrane domain protein α3-integrin showed a small increase 
(1,9-fold) in CNF. On the other hand, the staining of the other basal membrane domain 
protein in the analysis, β-dystroglycan, was reduced (2,6-fold). The only protein of the 
apical membrane domain included to the analysis was podocalyxin, staining of which 
showed slight decrease (1,2-fold). 
 
 
Table 7 CNF staining in CNF. This table collects the main findings of the study. NHK, normal 
human kidney. 
Proteins Number of glomeruli Median (IQR) 
  NHK CNF NHK CNF 
Regulation 
(fold change) 
Neph1 83 83 6,4 (7,9) 0,1 (0,2) down (45,8) 
Fat1 84 84 1,6 (0,6) 0,6 (0,7) down (2,6) 
CD2AP 110 121 1,8 (3,2) 5,9 (3,9) up (3,3) 
ACTN4 89 108 1,4 (2,9) 2,9 (2,7) up (2,16) 
β-Dystroglycan 103 114 7,0 (2,7) 2,7 (4,0) down (2,6) 
 
 
4.4.2 Podocyte proteins in MCNS 
 
The staining of Neph1, FAT1, CD2AP, and ACTN4 was studied in the MCNS 
biopsy samples taken during proteinuria and in remission. In contrast to CNF 
kidneys, the staining of Neph1 was only marginally reduced (1.5- and 1.6-fold in 
MCNS with and without proteinuria, respectively), as was the staining of 
ACTN4 (1.5- and 1.6-fold in MCNS with and without proteinuria, respectively). 













5.1 Clinical characteristics of childhood MCNS (I) 
 
MCNS is the most common form of NS in children. It is a complex disorder with 
still elusive pathogenesis. It is usually associated with steroid sensitivity. While 
clear cut causative variants are not likely to have a major, wide-spread role in 
MCNS, the question if genetic variation has a minor or modifying effect on the 
disease phenotype is still very much an open one. As the course and severity of 
MCNS cannot be assessed by a simple DNA test it would be highly beneficial to 
find other predictors with prognostic value, such as demographic and clinical 
features of the patients. We mapped long-term outcome and clinical features of 
104 Finnish adults with history of childhood MCNS to define reliable risk 
factors. We also looked into the overall morbidity of the MCNS later in life. 
 
5.1.1 Clinical features and long-term outcome of childhood MCNS 
 
Based on our results a child at their first occurrence of MCNS has approximately 
a 20% chance of no relapses, a 65% chance of relapses limited to childhood and 
a 15% chance that the proteinuric episodes still occur in adulthood. The median 
expected number of relapses is three and the duration of the disease is five 
years. If the child becomes dependent of steroids or has more than ten episodes 
in childhood, the chance of proteinuric episodes in adulthood increases to over 
40%. A study by Skrzypczyk et al. (278) show similar results as patients with 
relapses in adulthood have mean value of ten relapses in childhood compared to 
the mean value of four relapses of the patients with childhood only condition. 
Skrzypczyk et al. also observed that steroid-dependency in childhood was more 
frequent in patients with relapses in adulthood but due to small patient number 
the difference was not statistically significant.  
 
Over all, the outcome in MCNS appears to be good. Previous studies with 
shorter follow-up times have reached this conclusion (218, 219, 278-280). The 
studies report that 5-19% of the patients had proteinuric episodes as adults, 
with the exception of Fakhouri et al. (280) who reported adulthood episodes in 
42% of the patients. This high percentage may be affected by their selection of 
patients who are mostly steroid dependent. 
 
Several studies have reported an association between MCNS and immunological 
disorders (asthma, allergy and autoimmune diseases) (223, 281). Our study is in 
concordance with these previous reports: the patients may have some—although 
not strong—tendency to autoimmune disorders. Both MCNS and in allergic 
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disorders show activation of Th2 helper cells and cytokines such as IL4 and IL13 
(282). In MCNS proteinuric episodes often start during viral infection and it is 
possible that immune mediators play a significant role in it. Abdel-Hafez et al. 
(283) suggest that there is no causal relationship between allergic disorders and 
MCNS but underlying immunological events lead to both conditions. In 
particular IL13 may mediate proteinuria in MCNS patients as it induces the 
expression of protein CD80 in the podocytes, which has been associated with 
proteinuria. However, as the association of immunological disorders and MCNS 
is so weak in our study, it may indicate that the extent of these mechanisms is 
limited. 
 
5.1.2 Clinical Predictors in MCNS 
 
MCNS it does not run in families as clearly as SRNS is known to do. Thus, 
family history is not a comprehensive predictor of SSNS. However, there have 
been studies reporting familial SSNS in different parts of the world (284-286). 
Most of these incidences involve patients from consanguineous families that 
explain the probable accumulation of various genetic factors. Recently Gee et al. 
(160) reported two consanguineous Turkish families with monogenic cause for 
SSNS, homozygous variants in EMP2 gene. Consanguinity, however, is not 
always the case. Ruf et al., (284) carried out a linkage analysis and pinpointed 
SSNS causing locus (SSNS1) on chromosome 2p in one family. However, since 
then the genes of this locus have not been associated to familial SSNS in larger 
scale. Genetic heterogeneity seems to be explicit in MCNS inheritance and 
mapping out the family history and especially the known consanguineous 
marriages in the family may provide relevant information. 
 
5.2 Genetic variation in INS (I, II, III) 
 
The genetic background of majority of INS cases is still undiscovered. Most 
findings concern SRNS cases, which have revealed causative variants in 
podocyte protein coding genes but this subset is only approximately 30% of all 
reported cases and majority is still undefined. In SSNS causative genetic 
variants are rare. This is not unexpected as SSNS generally is considered a 
complex trait. Genetic variants may however play a minor or modifying role in 
the disease phenotype. The best predictor of the severity of the disease is the 
patient’s response to steroids but even that is not always reliable and initial 
response may change in time. Prolonged GC medication carries the risk of 
severe side effects including obesity, Cushing syndrome, hypertension, bone 
disease, growth retardation, striae, cataracts and behavioral disturbances (287). 
If patient’s response to GC medication could be reliably predicted at the time of 
diagnosis, the patients could get suitable treatment faster and avoid useless 
damaging medication. We looked into podocyte protein coding genes in MCNS 
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and SRNS patients and known variants in genes coding for other functional 
kidney molecules and proteins involved in steroid metabolism in INS patients to 
find out their usefulness in predicting the disease phenotype.  
 
5.2.1 Variants in podocyte protein coding genes in MCNS 
 
An attractive hypothesis is that the protein leakage in MCNS is caused by a 
combination of structural weaknesses and transient, circumstantial factors, 
such as T-cell cytokines. As the podocyte foot processes and the SD play an 
essential role in protein retention and are found to be damaged in certain other 
forms of NS, genes coding for proteins involved in this cellular structure were of 
interest to us.  
 
We carried out direct sequencing of exons and exon/intron boundaries of 
NPHS1, NPHS2 and NEPH1. Few variants in these essential podocyte protein-
coding genes were found, which leads to the conclusion that their meaning to 
the development of the MCNS condition is limited and minor. Other studies 
have reached similar conclusion. Kyrieleis et al. (288) found nothing but three 
heterozygous variants in NPHS1, and in NPHS2 only p.R229Q as a 
heterozygote. The other genes in their study (CD2AP and ACTN4) revealed no 
variants. Gbadegesin et al. (289) analysed NPHS2 and WT1 patients with 
steroid dependant or frequently relapsing NS and found no variants.  
 
Interestingly, in our study more variants accumulated to MCNS patients than to 
controls in NPHS1, but the pathogenic or modifying role of the variants is 
unclear and as the difference between patients and controls was small, little can 
be said about their significance to the MCNS phenotype in this population.  
 
5.2.2 Podocyte protein coding genes in the Finnish pediatric 
patients with SRNS 
 
Internationally, SRNS patients with determined causative variants 
predominantly present with histological finding FSGS (185). In the Finnish 
population FSGS is rarer than in other populations in general (2 vs. 4-8%, 
(218)). The reason for this is not known. We were curious if the frequency and 
nature of genetic variants in podocyte protein genes in Finland were comparable 
to those found elsewhere in the world or if the there was something in the 
Finnish genetic makeup that could explain the difference in prevalence.  
 
Few variants were discovered in NPHS1, NPHS2 and NEPH1. Most notably one 
of the twelve sporadic SRNS cases in the study had an amino acid changing 
variants in NPHS2, p.P341R in one allele and p.R229Q in two alleles. SRNS was 
diagnosed in this patient at the age of six and she is now waiting for the kidney 
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transplant at the age of 19 years. p.R229Q is a curious variant, pathogenicity of 
which have been contemplated during the years. It is associated with late-onset 
SRNS and albuminuria in general population but is also observed as a 
homozygote in healthy controls (290, 291) Recently, Tory et al. (190) suggested 
that it is only pathogenic together with another disease causing NPHS2 variant 
(compound heterozygosity), and that its pathogenicity is dependent on the 
position of the other variant. As p.P341R variant is in exon 8 this finding is in 
accordance with this proposed model. 
 
While Neph1 is associated with NS only in animal models (93) and NPHS1 
variants are predominantly found in congenital NS, the frequency of disease-
causing NPHS2 variants in sporadic SRNS is reported to be 10-28% (179, 180, 
292). In the cohort included in this study there was only one patient with 
potentially disease causing variants in the gene. This is slightly less than 
anticipated based on literature (8,3% vs. 10-28%). Frequencies of disease-
causing variants in the genes behind SRNS are known to differ between 
populations (293, 294). FSGS is relatively rare in Finland and it is possible that 
lack of NPHS2 variation is the reason behind this. However, the cohort size in 
this study is insufficient to draw conclusions, and larger scale study must be 
conducted in order to clarify the matter. 
 
5.2.3 Single nucleotide polymorphisms in INS 
 
We genotyped eleven SNPs from eight genes (nNOS, IL-12, MIF, Angptl4, 
GPC5, MDR1, NR3C1 and GLCCI1), which had previously been studied in 
relation to INS and proteinuric animal models. No great differences were 
observed between patients and controls, and all in all the observed associations 
between SNPs and clinical features were modest. 
 
5.2.3.1 The functional kidney molecules 
 
Alasehirli et al. (275) found that in nNOS gene polymorphism rs2682826 the TT 
genotype was associated with INS but not with GC responsiveness. NO 
attenuates many functions in the kidney and all forms of NOS are expressed in 
the kidney but the role of NO in renal disease is unclear. We did not see any 
association of rs2682826 genotypes to INS nor to any clinical features of the 
disease.  
 
Our results of the two cytokines, IL-13 and MIF were also negative. While Wei et 
al. (274) reported that 3’UTR SNPs of the IL-13 gene correlate with long term 
out-come of INS, we did not see any association between the analysed SNP and 
the number of relapses, response to medication, or any other feature. MIF is 
counter-regulated by GCs. Vivarelli et al. (240) found that the frequency of C 
allele of SNP rs755622 was higher in Italian patients than in controls and higher 
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in SRNS than in SSNS. Similarly, Berdeli et al. (239) found that GC genotype 
and C allele was higher in patients than in controls and CC genotype was more 
frequent in patients with SRNS than in those with SSNS. On the other hand, this 
association did not rise in a study of Korean patients by Choi et al. (249). 
Similarly, our study didn’t reveal any association between rs755622 SNP and 
INS or any of the clinical parameters. Different studies naturally use patients 
from different populations and population differences in allele frequencies 
cannot be ruled out. 
 
Angptl4 is a secretory protein involved in lipid metabolism and its increased 
expression has been observed in podocytes and circulation in human and 
experimental INS (229, 295). The genetic variant SNP rs1044250 in exon 6 
leads to amino acid change p.T266M and the homozygous C genotype of this 
variant has been associated with lower plasma Angptl4 levels (296). Recently, 
Clement et al. (297) discovered that increased circulating Angptl4 abates 
proteinuria but at the cost of inducing hypertriglyceridemia. In our analysis the 
C allele was more frequent in patients who received other IS drug medication in 
addition to GCs (72 vs. 54%, p=0,0228) but we did not see association of SNP 
genotypes to the occurrence of INS or clinical severity of the disorder. 
 
Recently, Okamoto et al. (175) found an association between glypican-5 (GPC5) 
gene variants and acquired NS (focal segmental glomerulosclerosis, proteinuric 
IgA-nephropathy) using a genome wide association study and replication 
analysis. They showed that glypican-5 is localized on the cell surface 
membranes of the podocyte and that GPC5 SNP rs16946160 risk genotype (AA) 
was associated with higher expression of the protein. In this study, we observed 
an association between rs16946160 A allele and early disease onset (16 vs. 5%, 
p=0.0421) but we did not find an association between the SNP and INS in 
general. It is, however, notable that none of our patients and only one of the 
controls carried the AA genotype. Okamoto et al. (175) found the A allele 
frequency of controls to be 0.168 and dbSNP (www.ncbi.nlm.nih.gov/snp) puts 
it at 0.161. In this study, it was only 0.08. Thus, it is possible that due to the 
frequency differences between populations the association between the risk 
genotype and INS is not visible in our patients. 
 
5.2.3.2 Glucocorticoid metabolism related molecules 
 
MDR1 gene codes for a membranous P-gp, multi-drug transporter expressed in 
the proximal tubular cells. Certain SNPs in MDR1 gene are found to affect the 
expression of the gene or activity of the protein it codes. The common SNP 
rs1045642 in exon 26 has garnered a lot of attention. It is a synonymous 
substitution and it may not be causal itself but linked with another variant or 
have an effect on DNA structure or RNA stability (276). Of the other two 
common SNPs in this study rs2032582 does lead to amino acid change, 
p.Ala899Ser/Thr. This variant is suggested to increase the drug resistance of the 
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cell (298, 299). The data on the significance of these SNPs from different studies 
are contradictory. The distribution of rs2032582 genotypes was found to be 
significantly different in healthy controls compared to patients in Indian and 
Egyptian populations (250, 276) while studies with Polish and Korean subjects 
did not find the association (248, 249). 
 
All three MDR1 SNPs showed association with treatment choices, T allele and 
TT genotype being more common in patients who needed other IS drugs 
compared to those who were only medicated with GCs, which indicates that T 
and TT are associated with more complicated form of the disease. Surprisingly, 
only rs1045642 showed significant association between genotype distribution 
and GC responsiveness (T allele was more frequent in poor responders), 
although it must be noted that only ten of our patients were not responsive to 
GCs; this small cohort size may affect these results.  
 
We did not discover any difference between the Finnish patients and controls in 
rs2032582 genotypes. Wasilewska et al. (248), Jafar et al. (250) and Youssef et 
al. (276) found an association between rs1045642 and NS (allele T and genotype 
TT was higher in patients) while Choi et al. (249) did not. Again, population 
differences may play a role. Youssef et al. (276) compared rs1045642 allele 
frequencies in their Egyptian control subjects and found that the frequencies (C 
66.4%, T 33.6%) were consistent with frequencies previously reported in 
African populations but different from frequencies found in Caucasian, Asian 
and Indian populations (250, 300). In this study, these frequencies were nearly 
opposite (C 37.2%, T 62.8%) of those determined by Yussef et al. (276). This 
may affect the association between rs1045642 genotypes and NS that was 
observed in Egyptian population but not in Finnish. On the other hand, in our 
study population, MDR1 SNP rs1045642 CC genotype showed association with 
higher age of onset (20 vs. 0%). Youssef et al. (276) reported similar association 
for SNPS rs2032582 as well as rs1045642. Other studies did not show this 
association at all (248). More work should be put to revealing the population 
differences in allele and genotype frequencies and what effects those may have 
on the function of the protein. 
 
NR3C1 codes for GR that that plays a role in the regulation of many biological 
functions, including responsiveness to GC, and its functional variability may 
affect the response to GC medication. In some previous studies, G allele of SNP 
rs4142347, especially as a part of intron B three SNP haplotype, has been 
associated with increased GC sensitivity (236, 301) while others could not 
confirm the association (302). In our analysis, we did not see the SNPs 
association to medical regimes. However, we did find that patients with more 
than five relapses carried more frequently heterozygous GC genotype than those 
with less than five relapses (68 vs. 33%). Simultaneously, the amount of both CC 
and GG homozygotes was reduced in the over five relapses -group. Curiously, 
the allele distribution between over five relapses and fewer than five relapses -
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groups showed no difference. It is unclear if this is functionally relevant finding 
or merely an artifact. 
 
An interesting new gene in the context of INS is GLCCI1. Tantisira et al. (243) 
first showed that SNPs rs37973 and rs37972, which are in linkage 
disequilibrium, associated with poor responsiveness to GCs in asthmatic 
patients. Soon afterwards, Nishibori et al. (244) showed that Glcci1-protein is 
highly expressed in glomerular podocytes and its deficiency leads to proteinuria. 
Based on these findings, Cheong et al. (245) looked to see if these SNPs were 
playing a role in GC responsiveness in NS but could find no association. 
Similarly, we found no association between the alleles or genotypes of either 
SNP and GC responsiveness but the frequency of the rs37973 A allele was higher 
in patients who received other IS drugs compared to those who received only 
GC medication (67 vs. 50%). Also, the A allele was more frequent in patients 
with more than five relapses compared to those with fewer (70 vs. 52%). To our 
knowledge this association has not been looked into in other studies.  
 
5.2.3.3 Haplotype analysis of MDR1 SNPs 
 
In previous studies, Wasilewska et al. (248) reported significant association 
between SNPs rs1128503, rs2032582 and rs1045642 formed haplotype 
frequencies with steroid response time. Choi et al. (249) and Youssef et al. (276) 
also saw this association, although, interestingly, the major haplotype linked 
with this property varies between studies. We did not find this association and 
Cizmarikova et al. (277) reached similar conclusion. The most abundant 
haplotypes of our study were TTT and CGC. These two were predominant in 
patient samples with combined allele frequency of 70%. The remaining 30% was 
distributed between eight other haplotypes, none of them reaching 10% 
frequency. In control patients TTT and CGC were also the most common 
haplotypes but not as prevalent as the distribution was more diverse, five 
haplotypes had over 10% frequency. Previous studies have also shown that TTT 
and CGC are prevalent haplotypes both in patients and in control subjects (248, 
249, 276, 277). Interestingly, Choi et al. (249) and Youssef et al. (276) found 
haplotype TGC to have a frequency equal to TTT and CGC, and have association 
to steroid responsiveness while Cizmarikova et al. (277) found the frequency of 
TGC to be under 3% in both patients and in controls and have no association to 
any clinical attribute. Our results are similar to the latter study as TGC 
frequency was 7.8% in control samples and 4.2% in patients. Again it must be 





5.3 Podocyte protein coding genes in Finnish familial SRNS (III) 
 
5.3.1 Rare clinical course of familial SRNS  
 
Familial SRNS with causative NPHS2 variants is inherited recessively (OMIM 
600995). The disease in the Family AM follows dominant inheritance pattern. 
Nevertheless, all affected family members carried heterozygous NPHS2 deletion 
c.988_989delCT. None of the healthy family members did.  
 
Typically, NPHS2 variants lead to NS with onset before six years of age and 
development to ESRD in first decade of life (303). The course of the dominant 
SRNS usually has later onset in adolescence or even in adulthood (304, 305). In 
Family AM the disease onset is during early childhood but the slow progression 
and ESRD in adulthood sets it apart from typical NPHS2 cases. In a way, the 
disease course in Family AM combines features from both dominant and 
recessive forms of the SRNS. 
 
5.3.2 NPHS2 in the familial NS 
 
The NPHS2 sequence was analysed in several ways. First, it was among the 
genes we analysed using direct sequencing of exons and exon/intron 
boundaries, and then it was included to the NS gene panel that checked relevant 
intronic regions in addition to exon and exon/intron boundaries, and WGS 
analysis that covered all of the intronic and control regions in addition to the 
coding ones. In all of these analyses c.988_989delCT was the only variant found 
that was carried only by the affected patients in the family and none of their 
healthy family members or unrelated controls. 
 
As the NS in the family AM follows dominant inheritance pattern it is expected 
that the causative variant is a heterozygous one. However, that the variant 
should be in NPHS2 is a surprise. 
 
To the best of our knowledge this is the first time a NPHS2 variant is suggested 
to cause dominant NS. While numerous studies report patients with a single 
heterozygous variant the second one is assumed to go undetected (i.e. lying in 
the introns, promoter or in other control segments) or the found variant is 
dismissed as inconsequential (303). Also we suspected that the deletion 
c.988_989delCT would be only one of two variants and thus carried out several 
types of sequence analyses to find out if the affected patients had a second 
variant that would contribute to compound heterozygous state. As said, a 
second variant in the other allele of NPHS2 was not discovered. One intronic 
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variant was found in all affected included in the analysis, but that SNP is located 
in the same allele as the deletion and is inherited together with it. The intronic 
variant is carried also by I-1, the healthy mother of the first affected patient of 
the family. The second allele appears to be without significant variants. 
 
Disease course affected by the specific NPHS2 variants is not a unique 
phenomenon. Congenital and infantile onset is common with variants p.R138Q, 
p.R168H, and truncating variants (183, 306). Milder course with delayed onset 
and prolonged progression is also reported, and often associated with variant 
p.R229Q. Compound heterozygous cases where p.R229Q is one of the variants, 
the mean age of diagnosis is 17 years and ESRD is reached in 26 years on 
average (8). Homozygous p.R229Q seems not to cause SRNS (189, 307). Some 
suggest that p.R229Q acts a modifier for variants in other genes (189) while 
others claim, as mentioned before, its effects depend on the specific variant it is 
coupled with: p.R229Q is pathogenic when the other allele carries a variant in 
exon 7 or 8 (190). The course of SRNS seem to be affected by the specific 
variants in NPHS2; it is not just a question of a variant being pathogenic or 
benign. 
 
Wild type podocin has 384 amino acid residues. The c.988_989delCT truncates 
the C-terminus of the podocin leaving a protein of 343 amino acids and of these 
the last 14 are incorrectly formed by the frame shift. The C-terminus of podocin 
is thought to be involved in the protein binding: in the homodimerization of 
podocin as well as in interactions with other proteins, such as nephrin and 
CD2AP (308). Often the protein-protein interactions are facilitated by amino 
acid residue proline and c.988_989delCT truncation erases nine proline 
residues of the podocin. We carried out an immunoprecipitation analysis, which 
showed that the binding of truncated podocin to nephrin was not much altered 
from the wild type. Whether the homodimerization or other interactions are 
disturbed remains to be studied. Besides the erasure of the proline residues, The 
PredictProtein service estimates that the truncation causes small changes to the 
secondary and tertiary structures of the protein. This may lead to a situation 
where the truncated podocin may have a modest negative impact on the 
glomerular filtration barrier, which then leads to the exceptionally slow 
progression of the disease. This is, of course, mere speculation based on this 
data. More experiments are required to illuminate how the function of podocin 
is affected by the deletion c.988_989delCT.  
  
5.3.3 Other podocyte genes in familial SRNS 
 
In order to examine the possibility that the deletion c.988_989delCT is not the 
disease-causing variant in family AM, we carried out sequence analysis of other 
genes coding for podocyte proteins with emphasis on genes involved in 
dominant NS. Few variants were discovered but none that co-segregated with 
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the disease phenotype. This further emphasizes the possible role of 
c.988_989delCT as a causative variant. 
	  
5.4 Podocyte Proteins in kidney disease (IV) 
 
The cause of CNF is the nucleotide variants in NPHS1 leading to disruption of 
the amino acid sequence and absence of nephrin from the SD resulting in the 
failure of the structure (85). Using immunohistochemistry and CNF tissue 
sections, we looked into the changes in the expression of various podocyte-
expressed proteins to see how the lack of this essential structural and signaling 
protein affects other cellular aspects of the podocyte. We also examined the 
expression of few proteins in the podocytes of patients with MCNS to see if same 
cellular events happen in both diseases. 
 
5.4.1 Slit diaphragm proteins in CNF 
 
The expression of the SD proteins Neph1 and Fat1 was greatly reduced. This 
finding is in line with electron microscopic imaging of podocyte foot processes 
in CNF patients, which show the whole SD structure to be missing. Nephrin is 
the major component of the structure that forms homodimers to bridges over 
the slit gap and to which other components of the SD bind to. Neph1 is 
homologous to nephrin. In addition to its structural role in the SD Neph1 is 
involved in actin remodeling in injury (92). Mice lacking Neph1 are proteinuric 
and die perinatally (93) and similarly Fat1 knockout mice undergo foot process 
effacement, massive proteinuria and perinatal lethality (96, 308). This 
demonstrated their salient roles in SD function even though in neither of them 
human pathogenic variants have been found.  
 
Due to the essential function of nephrin as a SD scaffold or back bone on which 
the other components attach themselves, it makes sense that in its absence the 
other SD proteins would find it difficult to find their correct places or to anchor 
themselves properly. The poor expression of these three major SD proteins may 
explain the massive protein loss in CNF. 
 
5.4.2 Adaptor proteins in CNF 
 
The cytosolic adaptor proteins podocin, NCK1/2 and CD2AP connect the SD to 
the actin cytoskeleton. Interestingly, their expression was very close to controls 
in the case of podocin and moderately increased in the case of NCK1/2 and 
CD2AP. Decreased expression of CD2AP is leads to podocyte injury, apoptosis, 
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and proteinuria (309, 310). Its moderate up-regulation in CNF glomeruli may 
reflect the podocyte´s attempt to restore critical cellular functions. 
 
CD2AP and Nck1/2 facilitate actin cytoskeleton maintenance and 
reorganization that is promoted by their binding to phosphorylated nephrin. 
When rapid actin polymerization and reorganization is required during 
development and injury repair, Nck and its actin-binding associates are 
recruited (110). During a steady state, nephrin/CD2AP binding predominates 
(111, 112). It is curious, then, that in the absence of nephrin both Nck1/2 and 
CD2AP are upregulated modestly but CD2AP upregulation is over twice of that 
of Nck1/2 (3.3- vs. 1.4-fold). Whether their expression is independent of 
nephrin or if the modest increase in their staining is due to a reaction to SD 
failure in attempt to maintain the cytoskeletal architecture requires further 
research. 
 
All in all, adaptor proteins play a key role in correct localization of the SD 
proteins but the opposite does not appear to be true: the absence of nephrin and 
consequent reduction in other SD components does not greatly affect the 
adaptor protein staining. However, the precision of immunohistochemistry and 
light microscopy is not high enough to pinpoint the exact localization of the 
adapter proteins in the foot processes; there may be alterations that this 
experiment did not reveal.  
 
5.4.3 Actin cytoskeleton regulating proteins in CNF 
 
Of the three actin cytoskeleton regulating proteins ACTN4 and INF2 showed 
mildly increased staining while N-WASp staining was not significantly altered. 
Variants in ACTN4 coding gene are found in patients with AD form of SRNS and 
previously the upregulation of the protein has been seen in membranous 
nephropathy (311). Variants in INF2 are also associated with dominantly 
inherited SRNS and its mouse knockout models lead to actin reorganization. It 
also plays a role in lipid raft related trafficking of SD proteins (203). It is 
possible that the upregulation of INF2 is a reaction to the absence of nephrin; a 
desperate and doomed effort to counteract the failure to form the SD. However, 
the increases in the staining are not large and how they affect the actin 
cytoskeleton is not clear. 
 
5.4.4 Basel and apical domain proteins in CNF 
 
Podocytes are attached to the GBM mainly by the α3β1-integrin complex in the 
basal membrane domain of the foot processes (312). Mutations in ITGA3, 
coding for integrin-α3, lead to CNS with skin and lung disease (158) In our 
study, α3-integrin staining showed a small increase in CNF glomeruli. However, 
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the significance of this slight alteration in staining is still unclear. αβ-
dystroglycan complex also binds components of the GBM and is thought to play 
a role in the attachment of the foot processes to the GBM (56). Its expression 
pattern is altered in experimental proteinuric models and dystroglycan-null 
mice show moderate foot process effacement (61, 313). However, the alterations 
are so slight that some investigators suggest its function in the podocyte is 
mainly superfluous (62). Our results show that in CNF β-dystroglycan staining 
was moderately reduced. However, as we analysed the staining using light 
microscopy, it is difficult to say if the localization of the protein is exactly as it is 
in WT protein. 
 
One of the end-results of podocyte damage is thought to be podocyte 
detachment from the GBM and it has been suggested that the foot process 
effacement is a protective mechanism to save the podocytes from detachment. 
While the effacement of podocyte foot processes occurs in CNF glomerulus, the 
detachment from the GBM seems to be a rare event (145, 315). It is possible that 
the increased expression of α3β1-complex in the flattened foot processes adds to 
their “stickiness” to the GBM, and thus fights against the detachment. In this 
study, the nearly unaffected staining of podocalyxin, which in 
immunohistochemistry is often used as a podocyte marker, speaks against 
significant podocyte loss.  
 
5.4.5 Podocyte proteins in MCNS 
 
While much is known about the molecular basis of CNF and other inherited 
nephrotic syndromes, the role of podocytes in MCNS is still unclear. Podocyte 
effacement is seen in EM, but its correlation to proteinuric episodes is not 
accurate and it is still not clear whether these changes seen in EM are the cause 
or consequence of proteinuria (217). In immunohistochemistry, nephrin and 
podocin expression in MCNS kidneys has shown some variation from quite 
normal to significantly reduced (170, 217, 315). Mao et al. (315) studied the 
expression profiles of nephrin, podocin and CD2AP at mRNA level in Chinese 
children with MCNS and found podocin expression not to be affected and 
CD2AP to be lower in MCNS. We found CD2AP to be downregulated as well, but 
the difference was insignificantly slight. In fact in our study, all the perceived 
changes in expression were small, which in case of Neph1 is in sharp contrast to 
the findings in CNF. No statistically significant changes were found between 
MCNS with and without proteinuria groups. These findings suggest that the 
molecular architecture of the podocyte foot process is quite well preserved in 






This thesis concentrates on the analysis of genetic and clinical features to 
discover causative variants and predictive markers in childhood NS. We also 
looked into the effects of a known genetic injury to the podocyte structure. The 
main conclusions of this thesis study are: 
 
1. The outcome in MCNS is quite good. Genetics play a smaller role in its 
background than in some other forms of NS and reliably predicting its 
course at the time of onset is currently not possible. 
 
2. The genes coding for proteins involved in glucocorticoid metabolism, 
especially MDR1, probably play a role in modifying the INS phenotype 
but defining that role is challenging. Differences in allele frequencies 
between populations may hold significance. 
 
3. The specific NPHS2 variants have surprisingly large effect on the disease 
phenotype, affecting the age of onset, disease progression and even the 
mode of inheritance. The nature of the variant must be considered when 
carrying out a genetic analysis. 
 
4. Podocyte structure is maintained by communication and interaction 
between copious amount of proteins, and effects of the removal of such 
an involved protein as nephrin spreads to all compartments of the cell, 
but is especially damaging to the other SD proteins. However, 
considering how pronounced the observed damage to podocyte foot 
process structure in absence of nephrin is the magnitude of change in 
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